\PassOptionsToPackage{unicode=true}{hyperref} % options for packages loaded elsewhere
\PassOptionsToPackage{hyphens}{url}
\PassOptionsToPackage{dvipsnames,svgnames*,x11names*}{xcolor}
%
\documentclass[]{book}
\usepackage{lmodern}
\usepackage{amssymb,amsmath}
\usepackage{ifxetex,ifluatex}
\usepackage{fixltx2e} % provides \textsubscript
\ifnum 0\ifxetex 1\fi\ifluatex 1\fi=0 % if pdftex
  \usepackage[T1]{fontenc}
  \usepackage[utf8]{inputenc}
  \usepackage{textcomp} % provides euro and other symbols
\else % if luatex or xelatex
  \usepackage{unicode-math}
  \defaultfontfeatures{Ligatures=TeX,Scale=MatchLowercase}
\fi
% use upquote if available, for straight quotes in verbatim environments
\IfFileExists{upquote.sty}{\usepackage{upquote}}{}
% use microtype if available
\IfFileExists{microtype.sty}{%
\usepackage[]{microtype}
\UseMicrotypeSet[protrusion]{basicmath} % disable protrusion for tt fonts
}{}
\IfFileExists{parskip.sty}{%
\usepackage{parskip}
}{% else
\setlength{\parindent}{0pt}
\setlength{\parskip}{6pt plus 2pt minus 1pt}
}
\usepackage{xcolor}
\usepackage{hyperref}
\hypersetup{
            pdftitle={COVID-19 Correlates of Risk Analysis Report},
            pdfauthor={USG COVID-19 Response Biostatistics Team},
            colorlinks=true,
            linkcolor=Maroon,
            citecolor=Blue,
            urlcolor=Blue,
            breaklinks=true}
\urlstyle{same}  % don't use monospace font for urls
\usepackage{longtable,booktabs}
% Fix footnotes in tables (requires footnote package)
\IfFileExists{footnote.sty}{\usepackage{footnote}\makesavenoteenv{longtable}}{}
\usepackage{graphicx,grffile}
\makeatletter
\def\maxwidth{\ifdim\Gin@nat@width>\linewidth\linewidth\else\Gin@nat@width\fi}
\def\maxheight{\ifdim\Gin@nat@height>\textheight\textheight\else\Gin@nat@height\fi}
\makeatother
% Scale images if necessary, so that they will not overflow the page
% margins by default, and it is still possible to overwrite the defaults
% using explicit options in \includegraphics[width, height, ...]{}
\setkeys{Gin}{width=\maxwidth,height=\maxheight,keepaspectratio}
\setlength{\emergencystretch}{3em}  % prevent overfull lines
\providecommand{\tightlist}{%
  \setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}
\setcounter{secnumdepth}{5}
% Redefines (sub)paragraphs to behave more like sections
\ifx\paragraph\undefined\else
\let\oldparagraph\paragraph
\renewcommand{\paragraph}[1]{\oldparagraph{#1}\mbox{}}
\fi
\ifx\subparagraph\undefined\else
\let\oldsubparagraph\subparagraph
\renewcommand{\subparagraph}[1]{\oldsubparagraph{#1}\mbox{}}
\fi

% set default figure placement to htbp
\makeatletter
\def\fps@figure{htbp}
\makeatother

%\usepackage[maxfloats=256]{morefloats}
\maxdeadcycles=1000
\usepackage[margin=1in]{geometry}
\usepackage{float}
\usepackage{booktabs}
\usepackage[inline]{enumitem}
\usepackage{mathtools}
\usepackage{graphicx}
\usepackage[round]{natbib}
\usepackage{tikz}
\usepackage[english]{babel}
\usepackage{longtable}
\usepackage{color}
\usepackage{amssymb,amsmath,amsthm}
\usepackage{multirow}
\usepackage[titletoc,title]{appendix}
\usepackage{authblk}
\usepackage{setspace}
\usepackage{dsfont}
\usepackage[OT1]{fontenc}
\usepackage{subcaption}
\usepackage{refcount}

\newtheorem*{remark}{Remark}
\newtheorem{theorem}{Theorem}
\AtEndDocument{\refstepcounter{theorem}\label{finalthm}}
{
  \theoremstyle{definition}
  \newtheorem{assumption}{}
}
{
  \theoremstyle{definition}
  \newtheorem{assumptioniden}{}
}
{
  \theoremstyle{definition}
  \newtheorem{example}{Example}[section]
}
\DeclareMathOperator{\opt}{opt}
\DeclareMathOperator{\dr}{IF}
\newcommand{\hopt}{\hat h_{\opt}}
\newcommand{\supp}{\mathop{\mathrm{supp}}}
\renewcommand\theassumptioniden{{A}\arabic{assumptioniden}}
\renewcommand\theassumption{{C}\arabic{assumption}}
\renewcommand\theexample{\arabic{example}}

\newtheorem{lemma}{Lemma} \newtheorem{coro}{Corollary}
\newtheorem{definition}{Definition}
\DeclareMathOperator{\expit}{expit}
\DeclareMathOperator{\bern}{Bern}
\DeclareMathOperator{\logit}{logit} \DeclareMathOperator{\var}{Var}
\DeclareMathOperator{\Rem}{Rem} \newcommand{\pt}{\mbox{$p_0$}}
\newcommand{\Pt}{\mbox{$P_0$}} \newcommand{\pl}{\parallel}
\newcommand{\indep}{\mbox{$\perp\!\!\!\perp$}} \newcommand{\rs}{R}
\newcommand{\ds}{D^\dag} \newcommand{\dd}{\mathrm{d}}
\newcommand{\Pn}{\mathbb{P}_{n}}
\newcommand{\mut}{\mu_0}
\newcommand{\thetasub}{\hat\theta_{\mbox{\scriptsize sub}}(\delta)}
\newcommand{\thetare}{\hat\theta_{\mbox{\scriptsize re}}(\delta)}
\newcommand{\thetatmle}{\hat\theta_{\mbox{\scriptsize tmle}}(\delta)}
\newcommand{\thetaaipw}{\hat\theta(\delta)}
\newcommand{\hgd}{\hat g_\delta} \newcommand{\hm}{\hat m}
\newcommand{\one}{\mathds{1}} \renewcommand{\P}{\mathbb{P}}
\newcommand{\R}{\mathbb{R}} \renewcommand{\rmdefault}{ptm}
\newcommand{\E}{\mathbb{E}}
\newcommand{\M}{\mathcal{M}}
\newcommand{\1}{\mathbbm{1}}
\newcommand{\prob}{\mathbb{P}}
\renewenvironment{proof}{{\it Proof }}{\qed \\}
\DeclareMathOperator*{\argmin}{\arg\!\min}
\DeclarePairedDelimiterX{\norm}[1]{\lVert}{\rVert}{#1}
\usepackage{eso-pic,graphicx,transparent}
\usepackage{etoolbox}
\makeatletter
\providecommand{\subtitle}[1]{% add subtitle to \maketitle
  \apptocmd{\@title}{\par {\large #1 \par}}{}{}
}
\makeatother
\usepackage{float}
\usepackage{flafter}
\usepackage{booktabs}
\usepackage{longtable}
\usepackage{array}
\usepackage{multirow}
\usepackage{wrapfig}
\usepackage{colortbl}
\usepackage{pdflscape}
\usepackage{tabu}
\usepackage{threeparttable}
\usepackage{threeparttablex}
\usepackage[normalem]{ulem}
\usepackage{makecell}
\usepackage{xcolor}
\usepackage[]{natbib}
\bibliographystyle{apalike}

\title{COVID-19 Correlates of Risk Analysis Report}
\providecommand{\subtitle}[1]{}
\subtitle{mock Study}
\author{USG COVID-19 Response Biostatistics Team}
\date{March 29, 2021}

\begin{document}
\maketitle

{
\hypersetup{linkcolor=}
\setcounter{tocdepth}{1}
\tableofcontents
}
\listoftables
\listoffigures
\AddToShipoutPictureFG{
  \AtPageCenter{
    \makebox[0pt]{\rotatebox[origin=c]{45}{
      \scalebox{10}{\texttransparent{0.3}{MOCK}}}}}}

\hypertarget{cor-tabular}{%
\chapter{Summary Tables}\label{cor-tabular}}

\captionsetup{justification=raggedright,singlelinecheck=false}

\captionsetup[table]{labelformat=empty}

\begin{ThreePartTable}
\begin{TableNotes}
\item This table summarises the random subcohort, which
      was randomly sampled from the per-protocol individuals without a COVID failure
      event $<$ 7 days post Day 57. The sampling was stratified by the key baseline 
      covariates: assigned treatment arm, baseline SARS-CoV-2 status 
      (defined by serostatus and possibly also NAAT and/or RNA PCR testing), 
      any additional important demographic factors such as the randomization strata 
      (e.g., defined by age and/or co-morbidities).
\end{TableNotes}
\begin{longtable}[t]{>{\raggedright\arraybackslash}p{7cm}lll}
\caption{\label{tab:tabs}Table 1. Demographic and Clinical Characteristics at Baseline in 
      the baseline SARS-CoV-2 negative per-protocol cohort}\\
\toprule
Characteristics & \makecell[l]{Vaccine\\(N = 914)} & \makecell[l]{Placebo\\(N = 163)} & \makecell[l]{Total\\(N = 1077)}\\
\midrule
\endfirsthead
\caption[]{\textit{(continued)}}\\
\toprule
Characteristics & \makecell[l]{Vaccine\\(N = 914)} & \makecell[l]{Placebo\\(N = 163)} & \makecell[l]{Total\\(N = 1077)}\\
\midrule
\endhead

\endfoot
\bottomrule
\insertTableNotes
\endlastfoot
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Age}}\\
\hspace{1em}Age $<$ 65 & 432 (47.3\%) & 80 (49.1\%) & 512 (47.5\%)\\
\hspace{1em}Age $\geq$ 65 & 482 (52.7\%) & 83 (50.9\%) & 565 \vphantom{1} (52.5\%)\\
\hspace{1em}Mean (Range) & 58.6 (18.0, 85.0) & 59.0 (18.0, 85.0) & 58.7 (18.0, 85.0)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{BMI}}\\
\hspace{1em}Mean $\pm$ SD & 30.1 $\pm$ 7.0 & 29.6 $\pm$ 7.2 & 30.0 $\pm$ 7.0\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Sex}}\\
\hspace{1em}Female & 519 (56.8\%) & 87 (53.4\%) & 606 (56.3\%)\\
\hspace{1em}Male & 395 (43.2\%) & 76 (46.6\%) & 471 (43.7\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Race}}\\
\hspace{1em}White Non-Hispanic & 362 (43.8\%) & 67 (44.7\%) & 429 (43.9\%)\\
\hspace{1em}Black or African American & 195 (23.6\%) & 39 (26.0\%) & 234 (24.0\%)\\
\hspace{1em}Asian & 67 (8.1\%) & 12 (8.0\%) & 79 (8.1\%)\\
\hspace{1em}American Indian or Alaska Native & 13 (1.6\%) & 5 (3.3\%) & 18 (1.8\%)\\
\hspace{1em}Native Hawaiian or Other Pacific Islander & 17 (2.1\%) & 1 (0.7\%) & 18 (1.8\%)\\
\hspace{1em}Multiracial & 52 (6.3\%) & 8 (5.3\%) & 60 (6.1\%)\\
\hspace{1em}Other & 34 (4.1\%) & 4 (2.7\%) & 38 (3.9\%)\\
\hspace{1em}Not reported and unknown & 87 (10.5\%) & 14 (9.3\%) & 101 (10.3\%)\\
\hspace{1em}Communities of Color & 420 (53.7\%) & 73 (52.1\%) & 493 (53.5\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Hispanic or Latino ethnicity}}\\
\hspace{1em}Hispanic or Latino & 136 (14.9\%) & 20 (12.3\%) & 156 (14.5\%)\\
\hspace{1em}Not Hispanic or Latino & 690 (75.5\%) & 130 (79.8\%) & 820 (76.1\%)\\
\hspace{1em}Not reported and unknown & 88 (9.6\%) & 13 (8.0\%) & 101 (9.4\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Risk for Severe Covid-19}}\\
\hspace{1em}At-risk & 469 (51.3\%) & 84 (51.5\%) & 553 (51.3\%)\\
\hspace{1em}Not at-risk & 445 (48.7\%) & 79 (48.5\%) & 524 (48.7\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Age, Risk for Severe Covid-19}}\\
\hspace{1em}Age $<$ 65 At-risk & 214 (23.4\%) & 40 (24.5\%) & 254 (23.6\%)\\
\hspace{1em}Age $<$ 65 Not at-risk & 218 (23.9\%) & 40 (24.5\%) & 258 (24.0\%)\\
\hspace{1em}Age $\geq$ 65 & 482 (52.7\%) & 83 (50.9\%) & 565 (52.5\%)\\*
\end{longtable}
\end{ThreePartTable}

\clearpage

\begin{ThreePartTable}
\begin{TableNotes}
\item This table summarises the random subcohort, which
      was randomly sampled from the per-protocol individuals without a COVID failure
      event $<$ 7 days post Day 57. The sampling was stratified by the key baseline 
      covariates: assigned treatment arm, baseline SARS-CoV-2 status 
      (defined by serostatus and possibly also NAAT and/or RNA PCR testing), 
      any additional important demographic factors such as the randomization strata 
      (e.g., defined by age and/or co-morbidities).
\end{TableNotes}
\begin{longtable}[t]{>{\raggedright\arraybackslash}p{7cm}lll}
\caption{\label{tab:tabs}Table 2. Demographic and Clinical Characteristics at Baseline in 
      the baseline SARS-CoV-2 positive per-protocol cohort}\\
\toprule
Characteristics & \makecell[l]{Vaccine\\(N = 274)} & \makecell[l]{Placebo\\(N = 270)} & \makecell[l]{Total\\(N = 544)}\\
\midrule
\endfirsthead
\caption[]{\textit{(continued)}}\\
\toprule
Characteristics & \makecell[l]{Vaccine\\(N = 274)} & \makecell[l]{Placebo\\(N = 270)} & \makecell[l]{Total\\(N = 544)}\\
\midrule
\endhead

\endfoot
\bottomrule
\insertTableNotes
\endlastfoot
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Age}}\\
\hspace{1em}Age $<$ 65 & 146 (53.3\%) & 147 (54.4\%) & 293 (53.9\%)\\
\hspace{1em}Age $\geq$ 65 & 128 (46.7\%) & 123 (45.6\%) & 251 \vphantom{1} (46.1\%)\\
\hspace{1em}Mean (Range) & 56.0 (18.0, 85.0) & 55.8 (18.0, 85.0) & 55.9 (18.0, 85.0)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{BMI}}\\
\hspace{1em}Mean $\pm$ SD & 30.7 $\pm$ 6.8 & 30.1 $\pm$ 7.2 & 30.4 $\pm$ 7.0\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Sex}}\\
\hspace{1em}Female & 153 (55.8\%) & 155 (57.4\%) & 308 (56.6\%)\\
\hspace{1em}Male & 121 (44.2\%) & 115 (42.6\%) & 236 (43.4\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Race}}\\
\hspace{1em}White Non-Hispanic & 125 (49.8\%) & 121 (49.0\%) & 246 (49.4\%)\\
\hspace{1em}Black or African American & 52 (20.7\%) & 60 (24.3\%) & 112 (22.5\%)\\
\hspace{1em}Asian & 24 (9.6\%) & 13 (5.3\%) & 37 (7.4\%)\\
\hspace{1em}American Indian or Alaska Native & 6 (2.4\%) & 4 (1.6\%) & 10 (2.0\%)\\
\hspace{1em}Native Hawaiian or Other Pacific Islander & 5 (2.0\%) & 1 (0.4\%) & 6 (1.2\%)\\
\hspace{1em}Multiracial & 12 (4.8\%) & 19 (7.7\%) & 31 (6.2\%)\\
\hspace{1em}Other & 7 (2.8\%) & 5 (2.0\%) & 12 (2.4\%)\\
\hspace{1em}Not reported and unknown & 20 (8.0\%) & 24 (9.7\%) & 44 (8.8\%)\\
\hspace{1em}Communities of Color & 120 (49.0\%) & 111 (47.8\%) & 231 (48.4\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Hispanic or Latino ethnicity}}\\
\hspace{1em}Hispanic or Latino & 35 (12.8\%) & 38 (14.1\%) & 73 (13.4\%)\\
\hspace{1em}Not Hispanic or Latino & 217 (79.2\%) & 214 (79.3\%) & 431 (79.2\%)\\
\hspace{1em}Not reported and unknown & 22 (8.0\%) & 18 (6.7\%) & 40 (7.4\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Risk for Severe Covid-19}}\\
\hspace{1em}At-risk & 125 (45.6\%) & 123 (45.6\%) & 248 (45.6\%)\\
\hspace{1em}Not at-risk & 149 (54.4\%) & 147 (54.4\%) & 296 (54.4\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Age, Risk for Severe Covid-19}}\\
\hspace{1em}Age $<$ 65 At-risk & 73 (26.6\%) & 75 (27.8\%) & 148 (27.2\%)\\
\hspace{1em}Age $<$ 65 Not at-risk & 73 (26.6\%) & 72 (26.7\%) & 145 (26.7\%)\\
\hspace{1em}Age $\geq$ 65 & 128 (46.7\%) & 123 (45.6\%) & 251 (46.1\%)\\*
\end{longtable}
\end{ThreePartTable}

\clearpage

\newgeometry{top=0.1in, bottom=0.1in}

\begin{landscape}

\begin{ThreePartTable}
\begin{TableNotes}
\item *Cases are baseline negative per-protocol vaccine recipients with the
        symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days
        after the Day 57 study visit.  Non-cases/Controls are baseline negative
        per-protocol vaccine recipients sampled into the random subcohort with
        no evidence of SARS-CoV-2 infection up to the time of data cut.
\end{TableNotes}
\begin{longtable}[t]{>{\raggedright\arraybackslash}p{1cm}lllllllll}
\caption{\label{tab:tabs}Table 3. Antibody levels in the baseline SARS-CoV-2 negative
      per-protocol cohort (vaccine recipients)}\\
\toprule
\multicolumn{2}{c}{ } & \multicolumn{8}{c}{Baseline SARS-CoV-2 Negative Vaccine Recipients} \\
\cmidrule(l{3pt}r{3pt}){3-10}
\multicolumn{2}{c}{ } & \multicolumn{3}{c}{Cases*} & \multicolumn{3}{c}{Non-Cases/Control} & \multicolumn{2}{c}{Comparison} \\
\cmidrule(l{3pt}r{3pt}){3-5} \cmidrule(l{3pt}r{3pt}){6-8} \cmidrule(l{3pt}r{3pt}){9-10}
Visit & Marker & N & Resp rate & GMT/GMC & N & Resp rate & GMT/GMC & \makecell[l]{Resp Rate\\Difference} & GMTR/GMCR\\
\midrule
\endfirsthead
\caption[]{\textit{(continued)}}\\
\toprule
Visit & Marker & N & Resp rate & GMT/GMC & N & Resp rate & GMT/GMC & \makecell[l]{Resp Rate\\Difference} & GMTR/GMCR\\
\midrule
\endhead

\endfoot
\bottomrule
\insertTableNotes
\endlastfoot
Day 29 & Anti N IgG (IU/ml) & 11 & \makecell[l]{64.1/64.1 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{9163\\(3359, 24998)} & 903 & \makecell[l]{13230.9/13230.9 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{23718\\(20083, 28010)} & \makecell[l]{0\%\\(0\%, 0\%)} & \makecell[l]{0.39\\(0.14, 1.07)}\\
Day 29 & Anti RBD IgG (IU/ml) & 11 & \makecell[l]{64.1/64.1 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{9820\\(4734, 20366)} & 903 & \makecell[l]{13230.9/13230.9 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{23105\\(20011, 26677)} & \makecell[l]{0\%\\(0\%, 0\%)} & \makecell[l]{0.43\\(0.20, 0.89)}\\
Day 29 & Anti Spike IgG (IU/ml) & 11 & \makecell[l]{64.1/64.1 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{12852\\(7097, 23271)} & 903 & \makecell[l]{13230.9/13230.9 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{41328\\(37060, 46086)} & \makecell[l]{0\%\\(0\%, 0\%)} & \makecell[l]{0.31\\(0.17, 0.57)}\\
Day 29 & Pseudovirus-nAb ID50 & 11 & \makecell[l]{56.7/64.1 = 90.9\%\\(46.3\%, 99.1\%)} & \makecell[l]{37\\(16, 86)} & 903 & \makecell[l]{11676.4/13230.9 = 88.3\%\\(84.8\%, 91.1\%)} & \makecell[l]{107\\(91, 126)} & \makecell[l]{2.6\%\\(-42.1\%, 11.6\%)} & \makecell[l]{0.35\\(0.15, 0.82)}\\
Day 29 & Pseudovirus-nAb ID80 & 11 & \makecell[l]{56.1/64.1 = 81.8\%\\(42.0\%, 96.5\%)} & \makecell[l]{103\\(30, 351)} & 903 & \makecell[l]{12465.5/13230.9 = 94.2\%\\(91.6\%, 96.1\%)} & \makecell[l]{190\\(161, 223)} & \makecell[l]{-12.4\%\\(-52.3\%, 2.6\%)} & \makecell[l]{0.54\\(0.16, 1.87)}\\
\addlinespace
Day 57 & Anti N IgG (IU/ml) & 11 & \makecell[l]{64.1/64.1 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{110124\\(35353, 343038)} & 903 & \makecell[l]{13230.9/13230.9 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{327744\\(269226, 398981)} & \makecell[l]{0\%\\(0\%, 0\%)} & \makecell[l]{0.34\\(0.11, 1.06)}\\
Day 57 & Anti RBD IgG (IU/ml) & 11 & \makecell[l]{64.1/64.1 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{334195\\(161041, 693528)} & 903 & \makecell[l]{13230.9/13230.9 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{974227\\(829937, 1143602)} & \makecell[l]{0\%\\(0\%, 0\%)} & \makecell[l]{0.34\\(0.16, 0.72)}\\
Day 57 & Anti Spike IgG (IU/ml) & 11 & \makecell[l]{64.1/64.1 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{240794\\(105801, 548023)} & 903 & \makecell[l]{13230.9/13230.9 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{2116905\\(1856215, 2414208)} & \makecell[l]{0\%\\(0\%, 0\%)} & \makecell[l]{0.11\\(0.05, 0.26)}\\
Day 57 & Pseudovirus-nAb ID50 & 11 & \makecell[l]{64.1/64.1 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{188\\(73, 487)} & 903 & \makecell[l]{13095.3/13230.9 = 99.0\%\\(98.0\%, 99.5\%)} & \makecell[l]{1517\\(1244, 1850)} & \makecell[l]{1\%\\(0.5\%, 2\%)} & \makecell[l]{0.12\\(0.05, 0.33)}\\
Day 57 & Pseudovirus-nAb ID80 & 11 & \makecell[l]{64.1/64.1 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{350\\(165, 740)} & 903 & \makecell[l]{13110.7/13230.9 = 99.1\%\\(97.1\%, 99.7\%)} & \makecell[l]{2249\\(1829, 2766)} & \makecell[l]{0.9\%\\(0.3\%, 2.9\%)} & \makecell[l]{0.16\\(0.07, 0.34)}\\*
\end{longtable}
\end{ThreePartTable}


\clearpage

\begin{ThreePartTable}
\begin{TableNotes}
\item *Cases are baseline positive per-protocol vaccine recipients with the
        symptomatic infection COVID-19 primary endpoint diagnosed starting 7
        days after the Day 57 study visit.  Non-cases/Controls are baseline
        negative per-protocol vaccine recipients sampled into the random
        subcohort with no evidence of SARS-CoV-2 infection up to the time
        of data cut.
\end{TableNotes}
\begin{longtable}[t]{>{\raggedright\arraybackslash}p{1cm}lllllllll}
\caption{\label{tab:tabs}Table 4. Antibody levels in the baseline SARS-CoV-2 positive
      per-protocol cohort (vaccine recipients)}\\
\toprule
\multicolumn{2}{c}{ } & \multicolumn{8}{c}{Baseline SARS-CoV-2 Positive Vaccine Recipients} \\
\cmidrule(l{3pt}r{3pt}){3-10}
\multicolumn{2}{c}{ } & \multicolumn{3}{c}{Cases*} & \multicolumn{3}{c}{Non-Cases/Control} & \multicolumn{2}{c}{Comparison} \\
\cmidrule(l{3pt}r{3pt}){3-5} \cmidrule(l{3pt}r{3pt}){6-8} \cmidrule(l{3pt}r{3pt}){9-10}
Visit & Marker & N & Resp rate & GMT/GMC & N & Resp rate & GMT/GMC & \makecell[l]{Resp Rate\\Difference} & GMTR/GMCR\\
\midrule
\endfirsthead
\caption[]{\textit{(continued)}}\\
\toprule
Visit & Marker & N & Resp rate & GMT/GMC & N & Resp rate & GMT/GMC & \makecell[l]{Resp Rate\\Difference} & GMTR/GMCR\\
\midrule
\endhead

\endfoot
\bottomrule
\insertTableNotes
\endlastfoot
Day 29 & Anti N IgG (IU/ml) & 2 & 17.2/17.2 = 100.0\% & \makecell[l]{130813\\(3444, 4969160)} & 272 & \makecell[l]{1414.8/1414.8 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{43029\\(32995, 56114)} & 0\% & \makecell[l]{3.04\\(0.08, 116.61)}\\
Day 29 & Anti RBD IgG (IU/ml) & 2 & 17.2/17.2 = 100.0\% & \makecell[l]{153444\\(6865, 3429945)} & 272 & \makecell[l]{1414.8/1414.8 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{35885\\(27859, 46223)} & 0\% & \makecell[l]{4.28\\(0.19, 96.57)}\\
Day 29 & Anti Spike IgG (IU/ml) & 2 & 17.2/17.2 = 100.0\% & \makecell[l]{104737\\(14230, 770889)} & 272 & \makecell[l]{1414.8/1414.8 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{80297\\(65042, 99128)} & 0\% & \makecell[l]{1.30\\(0.18, 9.71)}\\
Day 29 & Pseudovirus-nAb ID50 & 2 & 17.2/17.2 = 100.0\% & \makecell[l]{323\\(71, 1472)} & 272 & \makecell[l]{1365.9/1414.8 = 96.5\%\\(91.4\%, 98.6\%)} & \makecell[l]{185\\(141, 244)} & 3.5\% & \makecell[l]{1.74\\(0.37, 8.13)}\\
Day 29 & Pseudovirus-nAb ID80 & 2 & 17.2/17.2 = 100.0\% & \makecell[l]{481\\(4, 60966)} & 272 & \makecell[l]{1390.1/1414.8 = 98.2\%\\(93.6\%, 99.5\%)} & \makecell[l]{428\\(320, 573)} & 1.8\% & \makecell[l]{1.12\\(0.01, 143.66)}\\
\addlinespace
Day 57 & Anti N IgG (IU/ml) & 2 & 17.2/17.2 = 100.0\% & \makecell[l]{2440779\\(43120, 138159231)} & 272 & \makecell[l]{1414.8/1414.8 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{985914\\(697182, 1394221)} & 0\% & \makecell[l]{2.48\\(0.04, 142.23)}\\
Day 57 & Anti RBD IgG (IU/ml) & 2 & 17.2/17.2 = 100.0\% & \makecell[l]{2749023\\(61314, 123253076)} & 272 & \makecell[l]{1414.8/1414.8 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{2328268\\(1802226, 3007855)} & 0\% & \makecell[l]{1.18\\(0.03, 53.40)}\\
Day 57 & Anti Spike IgG (IU/ml) & 2 & 17.2/17.2 = 100.0\% & \makecell[l]{3627856\\(538606, 24435925)} & 272 & \makecell[l]{1414.8/1414.8 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{5409865\\(4378235, 6684574)} & 0\% & \makecell[l]{0.67\\(0.10, 4.57)}\\
Day 57 & Pseudovirus-nAb ID50 & 2 & 17.2/17.2 = 100.0\% & \makecell[l]{1829\\(160, 20945)} & 272 & \makecell[l]{1414.8/1414.8 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{5816\\(3934, 8599)} & 0\% & \makecell[l]{0.31\\(0.03, 3.72)}\\
Day 57 & Pseudovirus-nAb ID80 & 2 & 17.2/17.2 = 100.0\% & \makecell[l]{5772\\(290, 114704)} & 272 & \makecell[l]{1414.8/1414.8 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{7960\\(5601, 11311)} & 0\% & \makecell[l]{0.73\\(0.04, 14.71)}\\*
\end{longtable}
\end{ThreePartTable}


\clearpage

\begin{ThreePartTable}
\begin{TableNotes}
\item *Cases are baseline negative per-protocol vaccine recipients with the
        symptomatic infection COVID-19 primary endpoint diagnosed starting 7
        days after the Day 57 study visit.  Non-cases/Controls are baseline
        negative per-protocol vaccine recipients sampled into the random
        subcohort with no evidence of SARS-CoV-2 infection up to the time of
        data cut.
\end{TableNotes}
\begin{longtable}[t]{>{\raggedright\arraybackslash}p{1cm}lllllllll}
\caption{\label{tab:tabs}Table 5. Antibody levels in the baseline SARS-CoV-2 positive
      per-protocol cohort (placebo recipients)}\\
\toprule
\multicolumn{2}{c}{ } & \multicolumn{8}{c}{Baseline SARS-CoV-2 Positive Placebo Recipients} \\
\cmidrule(l{3pt}r{3pt}){3-10}
\multicolumn{2}{c}{ } & \multicolumn{3}{c}{Cases*} & \multicolumn{3}{c}{Non-Cases/Control} & \multicolumn{2}{c}{Comparison} \\
\cmidrule(l{3pt}r{3pt}){3-5} \cmidrule(l{3pt}r{3pt}){6-8} \cmidrule(l{3pt}r{3pt}){9-10}
Visit & Marker & N & Resp rate & GMT/GMC & N & Resp rate & GMT/GMC & \makecell[l]{Resp Rate\\Difference} & GMTR/GMCR\\
\midrule
\endfirsthead
\caption[]{\textit{(continued)}}\\
\toprule
Visit & Marker & N & Resp rate & GMT/GMC & N & Resp rate & GMT/GMC & \makecell[l]{Resp Rate\\Difference} & GMTR/GMCR\\
\midrule
\endhead

\endfoot
\bottomrule
\insertTableNotes
\endlastfoot
Day 29 & Anti N IgG (IU/ml) & 2 & 4/4 = 100.0\% & \makecell[l]{44658\\(376, 5310188)} & 268 & \makecell[l]{1353/1353 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{12485\\(9430, 16531)} & 0\% & \makecell[l]{3.58\\(0.03, 428.83)}\\
Day 29 & Anti RBD IgG (IU/ml) & 2 & 4/4 = 100.0\% & \makecell[l]{42959\\(6946, 265696)} & 268 & \makecell[l]{1353/1353 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{12824\\(10117, 16255)} & 0\% & \makecell[l]{3.35\\(0.53, 21.04)}\\
Day 29 & Anti Spike IgG (IU/ml) & 2 & 4/4 = 100.0\% & \makecell[l]{37021\\(6048, 226609)} & 268 & \makecell[l]{1353/1353 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{18162\\(15129, 21803)} & 0\% & \makecell[l]{2.04\\(0.33, 12.59)}\\
Day 29 & Pseudovirus-nAb ID50 & 2 & 1.6/4 = 50.0\% & \makecell[l]{93\\(0, 28176)} & 268 & \makecell[l]{1138.2/1353 = 84.1\%\\(76.9\%, 89.4\%)} & \makecell[l]{51\\(40, 66)} & -34.1\% & \makecell[l]{1.80\\(0.01, 550.47)}\\
Day 29 & Pseudovirus-nAb ID80 & 2 & 4/4 = 100.0\% & \makecell[l]{372\\(107, 1290)} & 268 & \makecell[l]{1254.5/1353 = 92.7\%\\(86.8\%, 96.1\%)} & \makecell[l]{129\\(98, 169)} & 7.3\% & \makecell[l]{2.89\\(0.81, 10.32)}\\
\addlinespace
Day 57 & Anti N IgG (IU/ml) & 2 & 4/4 = 100.0\% & \makecell[l]{652604\\(78974, 5392810)} & 268 & \makecell[l]{1353/1353 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{129537\\(92255, 181885)} & 0\% & \makecell[l]{5.04\\(0.59, 42.78)}\\
Day 57 & Anti RBD IgG (IU/ml) & 2 & 4/4 = 100.0\% & \makecell[l]{2348281\\(194513, 28349939)} & 268 & \makecell[l]{1353/1353 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{380897\\(298347, 486288)} & 0\% & \makecell[l]{6.17\\(0.50, 75.32)}\\
Day 57 & Anti Spike IgG (IU/ml) & 2 & 4/4 = 100.0\% & \makecell[l]{767715\\(603034, 977368)} & 268 & \makecell[l]{1353/1353 = 100.0\%\\(100.0\%, 100.0\%)} & \makecell[l]{676673\\(530979, 862343)} & 0\% & \makecell[l]{1.13\\(0.81, 1.60)}\\
Day 57 & Pseudovirus-nAb ID50 & 2 & 4/4 = 100.0\% & \makecell[l]{1515\\(18, 129242)} & 268 & \makecell[l]{1297.7/1353 = 95.9\%\\(90.6\%, 98.3\%)} & \makecell[l]{565\\(408, 782)} & 4.1\% & \makecell[l]{2.68\\(0.03, 231.59)}\\
Day 57 & Pseudovirus-nAb ID80 & 2 & 4/4 = 100.0\% & \makecell[l]{6066\\(474, 77675)} & 268 & \makecell[l]{1326.1/1353 = 98.0\%\\(93.2\%, 99.4\%)} & \makecell[l]{1319\\(934, 1864)} & 2\% & \makecell[l]{4.60\\(0.35, 60.26)}\\*
\end{longtable}
\end{ThreePartTable}


\clearpage
\end{landscape}

\hypertarget{ab-grapical}{%
\chapter{Graphical Descriptions of Antibody Marker Data}\label{ab-grapical}}

\hypertarget{boxplots}{%
\section{Boxplots}\label{boxplots}}

\hypertarget{baseline-seronegative}{%
\subsection{Baseline seronegative}\label{baseline-seronegative}}

\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/boxplots_Day57_trt_vaccine_x_cc_BaselineNeg_mock} 

}

\caption{Boxplots of D57 Ab markers: baseline negative vaccine arm.}\label{fig:unnamed-chunk-5}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/boxplots_Delta57overB_trt_vaccine_x_cc_BaselineNeg_mock} 

}

\caption{Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm.}\label{fig:unnamed-chunk-6}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/boxplots_Day29_trt_vaccine_x_cc_BaselineNeg_mock} 

}

\caption{Boxplots of D29 Ab markers: baseline negative vaccine arm.}\label{fig:unnamed-chunk-7}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/boxplots_Delta29overB_trt_vaccine_x_cc_BaselineNeg_mock} 

}

\caption{Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm.}\label{fig:unnamed-chunk-8}
\end{figure}

\clearpage

\hypertarget{baseline-seropositive}{%
\subsection{Baseline seropositive}\label{baseline-seropositive}}

\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/boxplots_Day57_trt_vaccine_x_cc_BaselinePos_mock} 

}

\caption{Boxplots of D57 Ab markers: baseline positive vaccine arm.}\label{fig:unnamed-chunk-9}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/boxplots_Delta57overB_trt_vaccine_x_cc_BaselinePos_mock} 

}

\caption{Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm.}\label{fig:unnamed-chunk-10}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/boxplots_Day29_trt_vaccine_x_cc_BaselinePos_mock} 

}

\caption{Boxplots of D29 Ab markers: baseline positive vaccine arm.}\label{fig:unnamed-chunk-11}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/boxplots_Delta29overB_trt_vaccine_x_cc_BaselinePos_mock} 

}

\caption{Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm.}\label{fig:unnamed-chunk-12}
\end{figure}

\clearpage

\hypertarget{weighted-rcdf-plots}{%
\section{Weighted RCDF plots}\label{weighted-rcdf-plots}}

\hypertarget{baseline-seronegative-1}{%
\subsection{Baseline seronegative}\label{baseline-seronegative-1}}

\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/Marker_RCDF_Day57_trt_by_event_status_bstatus_BaselineNeg_mock} 

}

\caption{RCDF plots for D57 Ab markers: baseline negative by treatment arm.}\label{fig:unnamed-chunk-13}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/Marker_RCDF_Delta57overB_trt_by_event_status_bstatus_BaselineNeg_mock} 

}

\caption{RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative by treatment arm.}\label{fig:unnamed-chunk-14}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/Marker_RCDF_Day29_trt_by_event_status_bstatus_BaselineNeg_mock} 

}

\caption{RCDF plots for D29 Ab markers: baseline negative by treatment arm.}\label{fig:unnamed-chunk-15}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/Marker_RCDF_Delta29overB_trt_by_event_status_bstatus_BaselineNeg_mock} 

}

\caption{RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative by treatment arm.}\label{fig:unnamed-chunk-16}
\end{figure}

\hypertarget{baseline-seropositive-1}{%
\subsection{Baseline seropositive}\label{baseline-seropositive-1}}

\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/Marker_RCDF_Day57_trt_by_event_status_bstatus_BaselinePos_mock} 

}

\caption{RCDF plots for D57 Ab markers: baseline positive by treatment arm.}\label{fig:unnamed-chunk-17}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/Marker_RCDF_Delta57overB_trt_by_event_status_bstatus_BaselinePos_mock} 

}

\caption{RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive by treatment arm.}\label{fig:unnamed-chunk-18}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/Marker_RCDF_Day29_trt_by_event_status_bstatus_BaselinePos_mock} 

}

\caption{RCDF plots for D29 Ab markers: baseline positive by treatment arm.}\label{fig:unnamed-chunk-19}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/Marker_RCDF_Delta29overB_trt_by_event_status_bstatus_BaselinePos_mock} 

}

\caption{RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive by treatment arm.}\label{fig:unnamed-chunk-20}
\end{figure}

\clearpage

\hypertarget{weighted-rcdf-plots-of-threshold-correlate-concentration-for-overall-vaccine-efficacy}{%
\section{Weighted RCDF plots of threshold correlate concentration for overall vaccine efficacy}\label{weighted-rcdf-plots-of-threshold-correlate-concentration-for-overall-vaccine-efficacy}}

\hypertarget{baseline-seronegative-2}{%
\subsection{Baseline seronegative}\label{baseline-seronegative-2}}

\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/RCDF_VE_Day57_trt_Vaccine_BaselineNeg_bindSpike_mock} 

}

\caption{Marker RCDF of D57 anti-Spike binding Ab: baseline negative vaccine arm}\label{fig:unnamed-chunk-21}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/RCDF_VE_Day57_trt_Vaccine_BaselineNeg_bindRBD_mock} 

}

\caption{Marker RCDF of D57 anti-RBD binding Ab: baseline negative vaccine arm}\label{fig:unnamed-chunk-22}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/RCDF_VE_Day57_trt_Vaccine_BaselineNeg_pseudoneutid50_mock} 

}

\caption{Marker RCDF of D57 PsV-nAb ID50: baseline negative vaccine arm}\label{fig:unnamed-chunk-23}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/RCDF_VE_Day57_trt_Vaccine_BaselineNeg_pseudoneutid80_mock} 

}

\caption{Marker RCDF of D57 PsV-nAb ID80: baseline negative vaccine arm}\label{fig:unnamed-chunk-24}
\end{figure}

\clearpage

\hypertarget{spaghetti-plots}{%
\section{Spaghetti plots}\label{spaghetti-plots}}

\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/spaghetti_plot_trt_BaselineNeg_mock} 

}

\caption{Spaghetti Plots of Marker Trajectory: baseline negative vaccine arm}\label{fig:unnamed-chunk-25}
\end{figure}
\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/spaghetti_plot_trt_BaselinePos_mock} 

}

\caption{Spaghetti Plots of Marker Trajectory: baseline positive vaccine arm}\label{fig:unnamed-chunk-26}
\end{figure}

\clearpage

\hypertarget{violin-and-line-plots}{%
\section{Violin and line plots}\label{violin-and-line-plots}}

\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm (2 timepoints)}\label{fig:unnamed-chunk-27}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm (2 timepoints)}\label{fig:unnamed-chunk-28}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm (2 timepoints)}\label{fig:unnamed-chunk-29}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm (2 timepoints)}\label{fig:unnamed-chunk-30}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (2 timepoints)}\label{fig:unnamed-chunk-31}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (2 timepoints)}\label{fig:unnamed-chunk-32}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (2 timepoints)}\label{fig:unnamed-chunk-33}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (2 timepoints)}\label{fig:unnamed-chunk-34}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm (2 timepoints)}\label{fig:unnamed-chunk-35}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm (2 timepoints)}\label{fig:unnamed-chunk-36}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm (2 timepoints)}\label{fig:unnamed-chunk-37}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm (2 timepoints)}\label{fig:unnamed-chunk-38}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (2 timepoints)}\label{fig:unnamed-chunk-39}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (2 timepoints)}\label{fig:unnamed-chunk-40}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (2 timepoints)}\label{fig:unnamed-chunk-41}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (2 timepoints)}\label{fig:unnamed-chunk-42}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm (3 timepoints)}\label{fig:unnamed-chunk-43}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm (3 timepoints)}\label{fig:unnamed-chunk-44}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm (3 timepoints)}\label{fig:unnamed-chunk-45}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm (3 timepoints)}\label{fig:unnamed-chunk-46}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (3 timepoints)}\label{fig:unnamed-chunk-47}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (3 timepoints)}\label{fig:unnamed-chunk-48}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (3 timepoints)}\label{fig:unnamed-chunk-49}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (3 timepoints)}\label{fig:unnamed-chunk-50}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm (3 timepoints)}\label{fig:unnamed-chunk-51}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm (3 timepoints)}\label{fig:unnamed-chunk-52}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm (3 timepoints)}\label{fig:unnamed-chunk-53}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm (3 timepoints)}\label{fig:unnamed-chunk-54}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (3 timepoints)}\label{fig:unnamed-chunk-55}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (3 timepoints)}\label{fig:unnamed-chunk-56}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (3 timepoints)}\label{fig:unnamed-chunk-57}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (3 timepoints)}\label{fig:unnamed-chunk-58}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_Age_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (2 timepoints)}\label{fig:unnamed-chunk-59}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_Age_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (2 timepoints)}\label{fig:unnamed-chunk-60}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_Age_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (2 timepoints)}\label{fig:unnamed-chunk-61}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_Age_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (2 timepoints)}\label{fig:unnamed-chunk-62}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_Age_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (2 timepoints)}\label{fig:unnamed-chunk-63}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_Age_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (2 timepoints)}\label{fig:unnamed-chunk-64}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_Age_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (2 timepoints)}\label{fig:unnamed-chunk-65}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_Age_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (2 timepoints)}\label{fig:unnamed-chunk-66}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_Age_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (2 timepoints)}\label{fig:unnamed-chunk-67}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_Age_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (2 timepoints)}\label{fig:unnamed-chunk-68}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_Age_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (2 timepoints)}\label{fig:unnamed-chunk-69}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_Age_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (2 timepoints)}\label{fig:unnamed-chunk-70}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_Age_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (2 timepoints)}\label{fig:unnamed-chunk-71}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_Age_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (2 timepoints)}\label{fig:unnamed-chunk-72}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_Age_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (2 timepoints)}\label{fig:unnamed-chunk-73}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_Age_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (2 timepoints)}\label{fig:unnamed-chunk-74}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_Age_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (3 timepoints)}\label{fig:unnamed-chunk-75}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_Age_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (3 timepoints)}\label{fig:unnamed-chunk-76}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_Age_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (3 timepoints)}\label{fig:unnamed-chunk-77}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_Age_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (3 timepoints)}\label{fig:unnamed-chunk-78}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_Age_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (3 timepoints)}\label{fig:unnamed-chunk-79}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_Age_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (3 timepoints)}\label{fig:unnamed-chunk-80}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_Age_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (3 timepoints)}\label{fig:unnamed-chunk-81}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_Age_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (3 timepoints)}\label{fig:unnamed-chunk-82}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_Age_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (3 timepoints)}\label{fig:unnamed-chunk-83}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_Age_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (3 timepoints)}\label{fig:unnamed-chunk-84}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_Age_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (3 timepoints)}\label{fig:unnamed-chunk-85}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_Age_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (3 timepoints)}\label{fig:unnamed-chunk-86}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_Age_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (3 timepoints)}\label{fig:unnamed-chunk-87}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_Age_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (3 timepoints)}\label{fig:unnamed-chunk-88}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_Age_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (3 timepoints)}\label{fig:unnamed-chunk-89}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_Age_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (3 timepoints)}\label{fig:unnamed-chunk-90}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_Risk_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-91}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_Risk_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-92}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_Risk_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-93}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_Risk_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-94}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_Risk_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-95}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_Risk_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-96}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_Risk_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-97}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_Risk_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-98}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_Risk_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-99}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_Risk_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-100}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_Risk_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-101}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_Risk_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-102}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_Risk_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-103}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_Risk_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-104}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_Risk_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-105}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_Risk_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (2 timepoints)}\label{fig:unnamed-chunk-106}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_Risk_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-107}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_Risk_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-108}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_Risk_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-109}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_Risk_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-110}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_Risk_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-111}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_Risk_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-112}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_Risk_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-113}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_Risk_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-114}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_Risk_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-115}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_Risk_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-116}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_Risk_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-117}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_Risk_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-118}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_Risk_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-119}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_Risk_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-120}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_Risk_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-121}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_Risk_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (3 timepoints)}\label{fig:unnamed-chunk-122}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-123}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-124}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-125}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-126}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-127}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-128}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-129}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-130}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-131}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-132}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-133}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-134}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-135}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-136}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-137}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_Age_Risk_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (2 timepoints)}\label{fig:unnamed-chunk-138}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-139}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-140}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-141}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-142}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-143}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-144}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-145}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-146}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-147}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-148}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-149}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-150}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-151}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-152}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-153}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_Age_Risk_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (3 timepoints)}\label{fig:unnamed-chunk-154}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_Sex_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-155}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_Sex_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-156}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_Sex_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-157}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_Sex_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-158}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_Sex_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-159}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_Sex_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-160}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_Sex_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-161}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_Sex_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-162}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_Sex_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-163}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_Sex_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-164}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_Sex_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-165}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_Sex_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-166}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_Sex_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-167}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_Sex_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-168}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_Sex_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-169}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_Sex_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (2 timepoints)}\label{fig:unnamed-chunk-170}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_Sex_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-171}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_Sex_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-172}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_Sex_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-173}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_Sex_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-174}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_Sex_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-175}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_Sex_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-176}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_Sex_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-177}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_Sex_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-178}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_Sex_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-179}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_Sex_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-180}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_Sex_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-181}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_Sex_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-182}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_Sex_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-183}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_Sex_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-184}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_Sex_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-185}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_Sex_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (3 timepoints)}\label{fig:unnamed-chunk-186}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-187}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-188}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-189}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-190}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-191}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-192}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-193}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-194}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-195}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-196}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-197}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-198}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-199}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-200}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-201}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-202}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-203}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-204}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-205}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-206}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-207}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-208}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-209}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-210}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-211}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-212}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-213}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-214}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-215}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-216}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-217}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-218}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-219}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-220}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-221}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-222}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-223}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-224}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-225}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-226}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-227}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-228}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-229}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-230}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-231}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-232}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-233}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_Dich_RaceEthnic_2tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (2 timepoints)}\label{fig:unnamed-chunk-234}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Placebo_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-235}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_Spike_Vaccine_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-236}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Placebo_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-237}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_RBD_Vaccine_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-238}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Placebo_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-239}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id50_Vaccine_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-240}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Placebo_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-241}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/linebox_pnAb_id80_Vaccine_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-242}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Placebo_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-243}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_Spike_Vaccine_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-244}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Placebo_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-245}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_RBD_Vaccine_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-246}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Placebo_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-247}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id50_Vaccine_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-248}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Placebo_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-249}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/violinbox_pnAb_id80_Vaccine_BaselineNeg_Dich_RaceEthnic_3tp_mock} 

}

\caption{violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (3 timepoints)}\label{fig:unnamed-chunk-250}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_Spike_Vaccine_BaselineNeg_Day1_mock} 

}

\caption{scatterplots of Binding Antibody to Spike: baseline negative vaccine arm at day 1}\label{fig:unnamed-chunk-251}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_Spike_Vaccine_BaselineNeg_Day29_mock} 

}

\caption{scatterplots of Binding Antibody to Spike: baseline negative vaccine arm at day 29}\label{fig:unnamed-chunk-252}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_Spike_Vaccine_BaselineNeg_Day57_mock} 

}

\caption{scatterplots of Binding Antibody to Spike: baseline negative vaccine arm at day 57}\label{fig:unnamed-chunk-253}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_RBD_Vaccine_BaselineNeg_Day1_mock} 

}

\caption{scatterplots of Binding Antibody to RBD: baseline negative vaccine arm at day 1}\label{fig:unnamed-chunk-254}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_RBD_Vaccine_BaselineNeg_Day29_mock} 

}

\caption{scatterplots of Binding Antibody to RBD: baseline negative vaccine arm at day 29}\label{fig:unnamed-chunk-255}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_RBD_Vaccine_BaselineNeg_Day57_mock} 

}

\caption{scatterplots of Binding Antibody to RBD: baseline negative vaccine arm at day 57}\label{fig:unnamed-chunk-256}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id50_Vaccine_BaselineNeg_Day1_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm at day 1}\label{fig:unnamed-chunk-257}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id50_Vaccine_BaselineNeg_Day29_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm at day 29}\label{fig:unnamed-chunk-258}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id50_Vaccine_BaselineNeg_Day57_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm at day 57}\label{fig:unnamed-chunk-259}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id80_Vaccine_BaselineNeg_Day1_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm at day 1}\label{fig:unnamed-chunk-260}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id80_Vaccine_BaselineNeg_Day29_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm at day 29}\label{fig:unnamed-chunk-261}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id80_Vaccine_BaselineNeg_Day57_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm at day 57}\label{fig:unnamed-chunk-262}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_Spike_all_Day1_mock} 

}

\caption{scatterplots of Binding Antibody to Spike: by arm at day 1}\label{fig:unnamed-chunk-263}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_Spike_all_Day29_mock} 

}

\caption{scatterplots of Binding Antibody to Spike: by arm at day 29}\label{fig:unnamed-chunk-264}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_Spike_all_Day57_mock} 

}

\caption{scatterplots of Binding Antibody to Spike: by arm at day 57}\label{fig:unnamed-chunk-265}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_RBD_all_Day1_mock} 

}

\caption{scatterplots of Binding Antibody to RBD: by arm at day 1}\label{fig:unnamed-chunk-266}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_RBD_all_Day29_mock} 

}

\caption{scatterplots of Binding Antibody to RBD: by arm at day 29}\label{fig:unnamed-chunk-267}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_RBD_all_Day57_mock} 

}

\caption{scatterplots of Binding Antibody to RBD: by arm at day 57}\label{fig:unnamed-chunk-268}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id50_all_Day1_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID50: by arm at day 1}\label{fig:unnamed-chunk-269}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id50_all_Day29_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID50: by arm at day 29}\label{fig:unnamed-chunk-270}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id50_all_Day57_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID50: by arm at day 57}\label{fig:unnamed-chunk-271}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id80_all_Day1_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID80: by arm at day 1}\label{fig:unnamed-chunk-272}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id80_all_Day29_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID80: by arm at day 29}\label{fig:unnamed-chunk-273}
\end{figure}

\clearpage
\begin{figure}[H]

{\centering \includegraphics[width=0.8\linewidth,]{/home/travis/build/CoVPN/correlates_reporting/cor_graphical/figs/scatter_pnAb_id80_all_Day57_mock} 

}

\caption{scatterplots of Pseudovirus Neutralization ID80: by arm at day 57}\label{fig:unnamed-chunk-274}
\end{figure}

\hypertarget{cor-coxph-Day57}{%
\chapter{Day 57 Univariate CoR: Cox Models of Risk}\label{cor-coxph-Day57}}

The main regression model is the Cox proportional hazards model. All plots are made with Cox models fit unless specified otherwise.

\hypertarget{hazard-ratios}{%
\section{Hazard ratios}\label{hazard-ratios}}

\begin{table}[H]
\caption{Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*}
\begin{center}
    \input{cor_coxph/output/D57/CoR_univariable_svycoxph_pretty_mock}\\
\end{center}
*Baseline covariates adjusted for: age in years, at risk or not, community of color or not
%, baseline risk score
. Average follow-up time \input{cor_coxph/output/D57/CoR_mean_followup_time_vacc_mock} days, maximum follow-up time \input{cor_coxph/output/D57/CoR_max_followup_time_vacc_mock} days.\\
**No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID; no. cases = number of this cohort with an observed COVID endpoints starting 7 days post Day 57 visit.

    %\label{tab:CoR_univariable_svycoxph_pretty_mock}
\end{table}

\begin{table}[H]
\caption{Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*}
\begin{center}
\setlength{\tabcolsep}{.5ex}
\input{cor_coxph/output/D57/CoR_univariable_svycoxph_cat_pretty_mock}\\
\end{center}
*Baseline covariates adjusted for: age in years, at risk or not, community of color or not
%, baseline risk score
. Average follow-up time \input{cor_coxph/output/D57/CoR_mean_followup_time_vacc_mock} days, maximum follow-up time \input{cor_coxph/output/D57/CoR_max_followup_time_vacc_mock} days.
Cutpoints:
%Day 57 cutpoints:
\input{cor_coxph/output/D57/cutpoints_Day57bindSpike_mock},  
\input{cor_coxph/output/D57/cutpoints_Day57bindRBD_mock},  
\input{cor_coxph/output/D57/cutpoints_Day57pseudoneutid50_mock},  
\input{cor_coxph/output/D57/cutpoints_Day57pseudoneutid80_mock}.
%fold-rise cutpoints:
%\input{cor_coxph/output/D57/cutpoints_Delta57overBbindSpike_mock},  
%\input{cor_coxph/output/D57/cutpoints_Delta57overBbindRBD_mock},  
%\input{cor_coxph/output/D57/cutpoints_Delta57overBpseudoneutid50_mock},  
%\input{cor_coxph/output/D57/cutpoints_Delta57overBpseudoneutid80_mock}.  
\\
**No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID at 7 days post Day 57 visit; no. cases = number of this cohort with an observed COVID endpoints.\\
***Generalized Wald-test p-value of the null hypothesis that the hazard rate is constant across the Lower, Middle, and Upper tertile groups.
    %\label{tab:CoR_univariable_svycoxph_cat_pretty_mock}
\end{table}
\begin{figure}[H]
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/hr_forest_bindSpike_mock}
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/hr_forest_bindRBD_mock}
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/hr_forest_pseudoneutid50_mock}
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/hr_forest_pseudoneutid80_mock}
    \caption{Forest plots of hazard ratios per 10-fold increase in the marker among baseline seronegative vaccine recipients and subgroups with 95\% point-wise confidence intervals.}
\end{figure}
\clearpage
\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/hr_forest_marginal_bindSpike_mock}
    \caption{Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to spike markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95\% point-wise confidence intervals.}
\end{figure}
\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/hr_forest_marginal_bindRBD_mock}
    \caption{Forest plots of hazard ratios per 10-fold increase in the  Day 57 binding Ab to RBD markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95\% point-wise confidence intervals.}
\end{figure}
\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/hr_forest_marginal_pseudoneutid50_mock}
    \caption{Forest plots of hazard ratios per 10-fold increase in the  Day 57 pseudo neut ID50 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95\% point-wise confidence intervals.}
\end{figure}

\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/hr_forest_marginal_pseudoneutid80_mock}
    \caption{Forest plots of hazard ratios per 10-fold increase in the  Day 57 pseudo neut ID80 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95\% point-wise confidence intervals.}
\end{figure}
\clearpage

\hypertarget{marginalized-risk-and-controlled-vaccine-efficacy-plots}{%
\section{Marginalized risk and controlled vaccine efficacy plots}\label{marginalized-risk-and-controlled-vaccine-efficacy-plots}}

\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/marginalized_risks1_mock}
    \caption{Marginalized cumulative risk by Day \protect\input{cor_coxph/output/D57/timepoints_cum_risk_mock} as functions of Day 57 markers (=s) among baseline seronegative vaccine recipients with 95\% bootstrap point-wise confidence bands. The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day \protect\input{cor_coxph/output/D57/timepoints_cum_risk_mock} and its 95\% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.}
\end{figure}
\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/marginalized_risks2_woplacebo_mock}
    \caption{Marginalized cumulative risk by Day \protect\input{cor_coxph/output/D57/timepoints_cum_risk_mock} as functions of Day 57 markers above a threshold ($\geq s$) among baseline seronegative vaccine recipients with 95\% bootstrap point-wise confidence bands (at least 5 cases are required). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day \protect\input{cor_coxph/output/D57/timepoints_cum_risk_mock} and its 95\% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.}
\end{figure}
\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/controlled_ve_curves_mock}
    \caption{Controlled VE with sensitivity analysis as functions of Day 57 markers (=s) among baseline seronegative vaccine recipients with 95\% bootstrap point-wise confidence bands. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.}
\end{figure}

\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D57/marginalized_risks_cat_mock}
    \caption{Marginalized cumulative incidence rate curves for trichotomized Day 57 markers among baseline seronegative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.}
\end{figure}

\clearpage

\hypertarget{cor-coxph-Day29}{%
\chapter{Day 29 Univariate CoR: Cox Models of Risk}\label{cor-coxph-Day29}}

The main regression model is the Cox proportional hazards model. All plots are made with Cox models fit unless specified otherwise.

\hypertarget{hazard-ratios-1}{%
\section{Hazard ratios}\label{hazard-ratios-1}}

\begin{table}[H]
\caption{Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*}
\begin{center}
    \input{cor_coxph/output/D29/CoR_univariable_svycoxph_pretty_mock}\\
\end{center}
*Baseline covariates adjusted for: age in years, at risk or not, community of color or not
%, baseline risk score
. Average follow-up time \input{cor_coxph/output/D29/CoR_mean_followup_time_vacc_mock} days, maximum follow-up time \input{cor_coxph/output/D29/CoR_max_followup_time_vacc_mock} days.\\
**No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID; no. cases = number of this cohort with an observed COVID endpoints starting 7 days post Day 29 visit.

    %\label{tab:CoR_univariable_svycoxph_pretty_mock}
\end{table}

\begin{table}[H]
\caption{Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*}
\begin{center}
\setlength{\tabcolsep}{.5ex}
\input{cor_coxph/output/D29/CoR_univariable_svycoxph_cat_pretty_mock}\\
\end{center}
*Baseline covariates adjusted for: age in years, at risk or not, community of color or not
%, baseline risk score
. Average follow-up time \input{cor_coxph/output/D29/CoR_mean_followup_time_vacc_mock} days, maximum follow-up time \input{cor_coxph/output/D29/CoR_max_followup_time_vacc_mock} days.
Cutpoints:
%Day 29 cutpoints:
\input{cor_coxph/output/D29/cutpoints_Day29bindSpike_mock},  
\input{cor_coxph/output/D29/cutpoints_Day29bindRBD_mock},  
\input{cor_coxph/output/D29/cutpoints_Day29pseudoneutid50_mock},  
\input{cor_coxph/output/D29/cutpoints_Day29pseudoneutid80_mock}.
%fold-rise cutpoints:
%\input{cor_coxph/output/D29/cutpoints_Delta29overBbindSpike_mock},  
%\input{cor_coxph/output/D29/cutpoints_Delta29overBbindRBD_mock},  
%\input{cor_coxph/output/D29/cutpoints_Delta29overBpseudoneutid50_mock},  
%\input{cor_coxph/output/D29/cutpoints_Delta29overBpseudoneutid80_mock}.  
\\
**No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID at 7 days post Day 29 visit; no. cases = number of this cohort with an observed COVID endpoints.\\
***Generalized Wald-test p-value of the null hypothesis that the hazard rate is constant across the Lower, Middle, and Upper tertile groups.
    %\label{tab:CoR_univariable_svycoxph_cat_pretty_mock}
\end{table}
\begin{figure}[H]
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/hr_forest_bindSpike_mock}
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/hr_forest_bindRBD_mock}
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/hr_forest_pseudoneutid50_mock}
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/hr_forest_pseudoneutid80_mock}
    \caption{Forest plots of hazard ratios per 10-fold increase in the marker among baseline seronegative vaccine recipients and subgroups with 95\% point-wise confidence intervals.}
\end{figure}
\clearpage
\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/hr_forest_marginal_bindSpike_mock}
    \caption{Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to spike markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95\% point-wise confidence intervals.}
\end{figure}
\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/hr_forest_marginal_bindRBD_mock}
    \caption{Forest plots of hazard ratios per 10-fold increase in the  Day 29 binding Ab to RBD markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95\% point-wise confidence intervals.}
\end{figure}
\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/hr_forest_marginal_pseudoneutid50_mock}
    \caption{Forest plots of hazard ratios per 10-fold increase in the  Day 29 pseudo neut ID50 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95\% point-wise confidence intervals.}
\end{figure}

\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/hr_forest_marginal_pseudoneutid80_mock}
    \caption{Forest plots of hazard ratios per 10-fold increase in the  Day 29 pseudo neut ID80 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95\% point-wise confidence intervals.}
\end{figure}
\clearpage

\hypertarget{marginalized-risk-and-controlled-vaccine-efficacy-plots-1}{%
\section{Marginalized risk and controlled vaccine efficacy plots}\label{marginalized-risk-and-controlled-vaccine-efficacy-plots-1}}

\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/marginalized_risks1_mock}
    \caption{Marginalized cumulative risk by Day \protect\input{cor_coxph/output/D29/timepoints_cum_risk_mock} as functions of Day 29 markers (=s) among baseline seronegative vaccine recipients with 95\% bootstrap point-wise confidence bands. The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day \protect\input{cor_coxph/output/D29/timepoints_cum_risk_mock} and its 95\% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.}
\end{figure}
\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/marginalized_risks2_woplacebo_mock}
    \caption{Marginalized cumulative risk by Day \protect\input{cor_coxph/output/D29/timepoints_cum_risk_mock} as functions of Day 29 markers above a threshold ($\geq s$) among baseline seronegative vaccine recipients with 95\% bootstrap point-wise confidence bands (at least 5 cases are required). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day \protect\input{cor_coxph/output/D29/timepoints_cum_risk_mock} and its 95\% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.}
\end{figure}
\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/controlled_ve_curves_mock}
    \caption{Controlled VE with sensitivity analysis as functions of Day 29 markers (=s) among baseline seronegative vaccine recipients with 95\% bootstrap point-wise confidence bands. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.}
\end{figure}

\begin{figure}[H]
    \centering
    \includegraphics[width=1\textwidth]{cor_coxph/output/D29/marginalized_risks_cat_mock}
    \caption{Marginalized cumulative incidence rate curves for trichotomized Day 29 markers among baseline seronegative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.}
\end{figure}

\hypertarget{cor-threshold}{%
\chapter{Univariate CoR: Nonparametric Threshold Modeling}\label{cor-threshold}}

An extension of the unadjusted nonparametric threshold-searching approach
developed in \citet{Donovan}, the covariate-adjusted TMLE-based approach developed by
van der Laan, Zhang, Gilbert (submitted) is used to estimate the so-called
threshold-response function \(E_X[ E[Y|S \geq s, X, A = 1]|A=1]\) for a range of
thresholds \(s\).Here, \(X\) is a set of baseline characteristics, \(A=1\) represents
the vaccine group, \(S\) is the biomarker/immune-response/correlate of interest,
and \(Y\) is the indicator of COVID disease before some time point \(t_f\). This
parameter can be viewed as a causal/covariate-adjusted version of the parameter \(P(Y=1|S \geq s, A=1)\). Intuitively, the threshold-response at a given threshold is the expected
probability of obtaining COVID disease if one experiences a
marker/immune-response value above that threshold. The threshold-response
function is estimated for each of the four Day 57 antibody markers, in each case
adjusting for the baseline covariates: baseline risk score, high risk
indicator, and underrepresented minority status. A parametric learner, selected
via cross-validation, is used for the covariate adjustment. A number of plots
and tables are reported:

\begin{enumerate}
\item A plot and table with risk estimates and point-wise 95\% confidence intervals
\item A plot and table with risk estimates and simultaneous 95\% confidence bands
\item Monotone-corrected versions of 1 and 2.
\end{enumerate}

A reverse cumulative distribution function curve estimated by the IPW NPMLE of the marker values is superimposed on the threshold-response plots
and a dashed red line is added to mark the threshold value after which no more
events are observed.

\newpage

\hypertarget{plots-and-tables-with-estimates-and-pointwise-confidence-interval-for-day-57}{%
\section{Plots and Tables with estimates and pointwise confidence interval for Day 57}\label{plots-and-tables-with-estimates-and-pointwise-confidence-interval-for-day-57}}

\newpage

\newpage

\hypertarget{day-57-spike-protein-binding-antibody}{%
\subsection{Day 57 Spike protein binding antibody}\label{day-57-spike-protein-binding-antibody}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_Day57bindSpike_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Spike protein binding antibody levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-347}Table of risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{4.536} & \cellcolor{gray!6}{3.44 * 10$^4$} & \cellcolor{gray!6}{0.00480} & \cellcolor{gray!6}{0.00353} & \cellcolor{gray!6}{0.00608}\\
5.413 & 2.59 * 10$^5$ & 0.00271 & 0.00173 & 0.00369\\
\cellcolor{gray!6}{5.797} & \cellcolor{gray!6}{6.27 * 10$^5$} & \cellcolor{gray!6}{0.00172} & \cellcolor{gray!6}{0.00090} & \cellcolor{gray!6}{0.00255}\\
6.165 & 1.46 * 10$^6$ & 0.00115 & 0.00040 & 0.00191\\
\cellcolor{gray!6}{6.405} & \cellcolor{gray!6}{2.54 * 10$^6$} & \cellcolor{gray!6}{0.00079} & \cellcolor{gray!6}{0.00008} & \cellcolor{gray!6}{0.00150}\\
6.622 & 4.19 * 10$^6$ & 0.00021 & 0.00000 & 0.00064\\
\cellcolor{gray!6}{6.820} & \cellcolor{gray!6}{6.61 * 10$^6$} & \cellcolor{gray!6}{0.00028} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00087}\\
7.127 & 1.34 * 10$^7$ & 0.00000 & 0.00000 & NA\\
\cellcolor{gray!6}{7.409} & \cellcolor{gray!6}{2.56 * 10$^7$} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{NA}\\
8.244 & 1.75 * 10$^8$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-rbd-binding-antibody}{%
\subsection{Day 57 RBD binding antibody}\label{day-57-rbd-binding-antibody}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_Day57bindRBD_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 RBD binding antibody levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-349}Table of risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{4.062} & \cellcolor{gray!6}{1.15 * 10$^4$} & \cellcolor{gray!6}{0.00490} & \cellcolor{gray!6}{0.00360} & \cellcolor{gray!6}{0.00619}\\
5.085 & 1.22 * 10$^5$ & 0.00405 & 0.00282 & 0.00529\\
\cellcolor{gray!6}{5.507} & \cellcolor{gray!6}{3.21 * 10$^5$} & \cellcolor{gray!6}{0.00377} & \cellcolor{gray!6}{0.00247} & \cellcolor{gray!6}{0.00507}\\
5.839 & 6.90 * 10$^5$ & 0.00288 & 0.00163 & 0.00414\\
\cellcolor{gray!6}{6.048} & \cellcolor{gray!6}{1.12 * 10$^6$} & \cellcolor{gray!6}{0.00238} & \cellcolor{gray!6}{0.00113} & \cellcolor{gray!6}{0.00364}\\
6.257 & 1.81 * 10$^6$ & 0.00159 & 0.00043 & 0.00275\\
\cellcolor{gray!6}{6.499} & \cellcolor{gray!6}{3.16 * 10$^6$} & \cellcolor{gray!6}{0.00131} & \cellcolor{gray!6}{0.00007} & \cellcolor{gray!6}{0.00255}\\
6.847 & 7.03 * 10$^6$ & 0.00043 & 0.00000 & 0.00134\\
\cellcolor{gray!6}{7.181} & \cellcolor{gray!6}{1.52 * 10$^7$} & \cellcolor{gray!6}{0.00087} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00279}\\
8.239 & 1.73 * 10$^8$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-pseudo-virus-neutralizing-antibody-50-titer}{%
\subsection{Day 57 Pseudo virus-neutralizing antibody (50\% titer)}\label{day-57-pseudo-virus-neutralizing-antibody-50-titer}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_Day57pseudoneutid50_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Pseudo virus-neutralizing antibody (50\% titer) levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-351}Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50\% titer) levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00508} & \cellcolor{gray!6}{0.00376} & \cellcolor{gray!6}{0.00639}\\
2.033 & 1.08 * 10$^2$ & 0.00390 & 0.00268 & 0.00512\\
\cellcolor{gray!6}{2.447} & \cellcolor{gray!6}{2.80 * 10$^2$} & \cellcolor{gray!6}{0.00347} & \cellcolor{gray!6}{0.00223} & \cellcolor{gray!6}{0.00471}\\
2.913 & 8.18 * 10$^2$ & 0.00265 & 0.00145 & 0.00385\\
\cellcolor{gray!6}{3.196} & \cellcolor{gray!6}{1.57 * 10$^3$} & \cellcolor{gray!6}{0.00235} & \cellcolor{gray!6}{0.00112} & \cellcolor{gray!6}{0.00358}\\
3.464 & 2.91 * 10$^3$ & 0.00115 & 0.00016 & 0.00215\\
\cellcolor{gray!6}{3.736} & \cellcolor{gray!6}{5.45 * 10$^3$} & \cellcolor{gray!6}{0.00134} & \cellcolor{gray!6}{0.00013} & \cellcolor{gray!6}{0.00255}\\
4.123 & 1.33 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\cellcolor{gray!6}{4.629} & \cellcolor{gray!6}{4.26 * 10$^4$} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{NA}\\
5.730 & 5.37 * 10$^5$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-pseudo-virus-neutralizing-antibody-80-titer}{%
\subsection{Day 57 Pseudo virus-neutralizing antibody (80\% titer)}\label{day-57-pseudo-virus-neutralizing-antibody-80-titer}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_Day57pseudoneutid80_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Pseudo virus-neutralizing antibody (80\% titer) levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-353}Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80\% titer) levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{1.289} & \cellcolor{gray!6}{1.95 * 10$^1$} & \cellcolor{gray!6}{0.00514} & \cellcolor{gray!6}{0.00381} & \cellcolor{gray!6}{0.00647}\\
2.368 & 2.33 * 10$^2$ & 0.00469 & 0.00334 & 0.00605\\
\cellcolor{gray!6}{2.755} & \cellcolor{gray!6}{5.69 * 10$^2$} & \cellcolor{gray!6}{0.00428} & \cellcolor{gray!6}{0.00290} & \cellcolor{gray!6}{0.00565}\\
3.104 & 1.27 * 10$^3$ & 0.00343 & 0.00203 & 0.00482\\
\cellcolor{gray!6}{3.373} & \cellcolor{gray!6}{2.36 * 10$^3$} & \cellcolor{gray!6}{0.00310} & \cellcolor{gray!6}{0.00169} & \cellcolor{gray!6}{0.00452}\\
3.624 & 4.21 * 10$^3$ & 0.00284 & 0.00130 & 0.00438\\
\cellcolor{gray!6}{3.909} & \cellcolor{gray!6}{8.11 * 10$^3$} & \cellcolor{gray!6}{0.00244} & \cellcolor{gray!6}{0.00085} & \cellcolor{gray!6}{0.00404}\\
4.259 & 1.82 * 10$^4$ & 0.00206 & 0.00013 & 0.00400\\
\cellcolor{gray!6}{4.676} & \cellcolor{gray!6}{4.74 * 10$^4$} & \cellcolor{gray!6}{0.00256} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00567}\\
5.796 & 6.25 * 10$^5$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\hypertarget{plots-and-tables-with-estimates-and-pointwise-confidence-intervals-for-day-29}{%
\section{Plots and Tables with estimates and pointwise confidence intervals for Day 29}\label{plots-and-tables-with-estimates-and-pointwise-confidence-intervals-for-day-29}}

\newpage

\newpage

\hypertarget{day-29-spike-protein-antibody}{%
\subsection{Day 29 Spike protein antibody}\label{day-29-spike-protein-antibody}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_Day29bindSpike_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Spike protein antibody levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-355}Table of risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{3.202} & \cellcolor{gray!6}{1.59 * 10$^3$} & \cellcolor{gray!6}{0.00567} & \cellcolor{gray!6}{0.00427} & \cellcolor{gray!6}{0.00707}\\
3.926 & 8.43 * 10$^3$ & 0.00476 & 0.00341 & 0.00611\\
\cellcolor{gray!6}{4.187} & \cellcolor{gray!6}{1.54 * 10$^4$} & \cellcolor{gray!6}{0.00460} & \cellcolor{gray!6}{0.00318} & \cellcolor{gray!6}{0.00602}\\
4.478 & 3.01 * 10$^4$ & 0.00355 & 0.00215 & 0.00494\\
\cellcolor{gray!6}{4.658} & \cellcolor{gray!6}{4.55 * 10$^4$} & \cellcolor{gray!6}{0.00278} & \cellcolor{gray!6}{0.00138} & \cellcolor{gray!6}{0.00419}\\
4.841 & 6.93 * 10$^4$ & 0.00230 & 0.00083 & 0.00377\\
\cellcolor{gray!6}{5.022} & \cellcolor{gray!6}{1.05 * 10$^5$} & \cellcolor{gray!6}{0.00182} & \cellcolor{gray!6}{0.00031} & \cellcolor{gray!6}{0.00332}\\
5.310 & 2.04 * 10$^5$ & 0.00147 & 0.00000 & 0.00353\\
\cellcolor{gray!6}{5.523} & \cellcolor{gray!6}{3.33 * 10$^5$} & \cellcolor{gray!6}{0.00132} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00393}\\
6.259 & 1.82 * 10$^6$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-rbd-binding-antibody}{%
\subsection{Day 29 RBD binding antibody}\label{day-29-rbd-binding-antibody}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_Day29bindRBD_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 RBD binding antibody levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-357}Table of risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{2.882} & \cellcolor{gray!6}{7.62 * 10$^2$} & \cellcolor{gray!6}{0.00576} & \cellcolor{gray!6}{0.00435} & \cellcolor{gray!6}{0.00718}\\
3.628 & 4.25 * 10$^3$ & 0.00523 & 0.00379 & 0.00666\\
\cellcolor{gray!6}{3.889} & \cellcolor{gray!6}{7.74 * 10$^3$} & \cellcolor{gray!6}{0.00459} & \cellcolor{gray!6}{0.00316} & \cellcolor{gray!6}{0.00602}\\
4.180 & 1.51 * 10$^4$ & 0.00434 & 0.00278 & 0.00589\\
\cellcolor{gray!6}{4.395} & \cellcolor{gray!6}{2.48 * 10$^4$} & \cellcolor{gray!6}{0.00486} & \cellcolor{gray!6}{0.00298} & \cellcolor{gray!6}{0.00674}\\
4.603 & 4.01 * 10$^4$ & 0.00414 & 0.00217 & 0.00611\\
\cellcolor{gray!6}{4.826} & \cellcolor{gray!6}{6.70 * 10$^4$} & \cellcolor{gray!6}{0.00365} & \cellcolor{gray!6}{0.00148} & \cellcolor{gray!6}{0.00583}\\
5.105 & 1.27 * 10$^5$ & 0.00104 & 0.00000 & 0.00253\\
\cellcolor{gray!6}{5.422} & \cellcolor{gray!6}{2.64 * 10$^5$} & \cellcolor{gray!6}{0.00097} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00298}\\
6.197 & 1.57 * 10$^6$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-pseudo-virus-neutralizing-antibody-50-titer}{%
\subsection{Day 29 Pseudo virus-neutralizing antibody (50\% titer)}\label{day-29-pseudo-virus-neutralizing-antibody-50-titer}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_Day29pseudoneutid50_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Pseudo virus-neutralizing antibody (50\% titer) levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-359}Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50\% titer) levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00585} & \cellcolor{gray!6}{0.00442} & \cellcolor{gray!6}{0.00727}\\
1.363 & 2.31 * 10$^1$ & 0.00470 & 0.00331 & 0.00609\\
\cellcolor{gray!6}{1.628} & \cellcolor{gray!6}{4.25 * 10$^1$} & \cellcolor{gray!6}{0.00469} & \cellcolor{gray!6}{0.00318} & \cellcolor{gray!6}{0.00619}\\
1.848 & 7.05 * 10$^1$ & 0.00451 & 0.00290 & 0.00611\\
\cellcolor{gray!6}{2.078} & \cellcolor{gray!6}{1.20 * 10$^2$} & \cellcolor{gray!6}{0.00399} & \cellcolor{gray!6}{0.00237} & \cellcolor{gray!6}{0.00561}\\
2.293 & 1.96 * 10$^2$ & 0.00343 & 0.00175 & 0.00511\\
\cellcolor{gray!6}{2.537} & \cellcolor{gray!6}{3.44 * 10$^2$} & \cellcolor{gray!6}{0.00143} & \cellcolor{gray!6}{0.00016} & \cellcolor{gray!6}{0.00270}\\
2.791 & 6.18 * 10$^2$ & 0.00091 & 0.00000 & 0.00217\\
\cellcolor{gray!6}{3.109} & \cellcolor{gray!6}{1.29 * 10$^3$} & \cellcolor{gray!6}{0.00199} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00481}\\
4.080 & 1.20 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-pseudo-virus-neutralizing-antibody-80-titer}{%
\subsection{Day 29 Pseudo virus-neutralizing antibody (80\% titer)}\label{day-29-pseudo-virus-neutralizing-antibody-80-titer}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_Day29pseudoneutid80_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Pseudo virus-neutralizing antibody (80\% titer) levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-361}Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80\% titer) levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00585} & \cellcolor{gray!6}{0.00442} & \cellcolor{gray!6}{0.00727}\\
1.525 & 3.35 * 10$^1$ & 0.00535 & 0.00387 & 0.00682\\
\cellcolor{gray!6}{1.840} & \cellcolor{gray!6}{6.92 * 10$^1$} & \cellcolor{gray!6}{0.00580} & \cellcolor{gray!6}{0.00412} & \cellcolor{gray!6}{0.00748}\\
2.049 & 1.12 * 10$^2$ & 0.00554 & 0.00379 & 0.00730\\
\cellcolor{gray!6}{2.276} & \cellcolor{gray!6}{1.89 * 10$^2$} & \cellcolor{gray!6}{0.00542} & \cellcolor{gray!6}{0.00350} & \cellcolor{gray!6}{0.00733}\\
2.583 & 3.83 * 10$^2$ & 0.00479 & 0.00269 & 0.00690\\
\cellcolor{gray!6}{2.785} & \cellcolor{gray!6}{6.10 * 10$^2$} & \cellcolor{gray!6}{0.00559} & \cellcolor{gray!6}{0.00288} & \cellcolor{gray!6}{0.00830}\\
3.039 & 1.09 * 10$^3$ & 0.00342 & 0.00095 & 0.00589\\
\cellcolor{gray!6}{3.351} & \cellcolor{gray!6}{2.24 * 10$^3$} & \cellcolor{gray!6}{0.00161} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00398}\\
4.285 & 1.93 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\hypertarget{plots-and-tables-with-estimates-and-pointwise-confidence-interval-for-day-57-monotone-corrected}{%
\section{Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)}\label{plots-and-tables-with-estimates-and-pointwise-confidence-interval-for-day-57-monotone-corrected}}

\newpage

\newpage

\hypertarget{day-57-spike-protein-binding-antibody-1}{%
\subsection{Day 57 Spike protein binding antibody}\label{day-57-spike-protein-binding-antibody-1}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_monotone_Day57bindSpike_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Spike protein binding antibody levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-363}Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{4.536} & \cellcolor{gray!6}{3.44 * 10$^4$} & \cellcolor{gray!6}{0.00480} & \cellcolor{gray!6}{0.00353} & \cellcolor{gray!6}{0.00608}\\
5.413 & 2.59 * 10$^5$ & 0.00271 & 0.00173 & 0.00369\\
\cellcolor{gray!6}{5.797} & \cellcolor{gray!6}{6.27 * 10$^5$} & \cellcolor{gray!6}{0.00172} & \cellcolor{gray!6}{0.00090} & \cellcolor{gray!6}{0.00255}\\
6.165 & 1.46 * 10$^6$ & 0.00115 & 0.00040 & 0.00191\\
\cellcolor{gray!6}{6.405} & \cellcolor{gray!6}{2.54 * 10$^6$} & \cellcolor{gray!6}{0.00083} & \cellcolor{gray!6}{0.00012} & \cellcolor{gray!6}{0.00153}\\
6.622 & 4.19 * 10$^6$ & 0.00024 & 0.00000 & 0.00067\\
\cellcolor{gray!6}{6.820} & \cellcolor{gray!6}{6.61 * 10$^6$} & \cellcolor{gray!6}{0.00024} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00083}\\
7.127 & 1.34 * 10$^7$ & 0.00000 & 0.00000 & NA\\
\cellcolor{gray!6}{7.409} & \cellcolor{gray!6}{2.56 * 10$^7$} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{NA}\\
8.244 & 1.75 * 10$^8$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-rbd-binding-antibody-1}{%
\subsection{Day 57 RBD binding antibody}\label{day-57-rbd-binding-antibody-1}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_monotone_Day57bindRBD_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 RBD binding antibody levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-365}Table of monotone-corrected risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{4.062} & \cellcolor{gray!6}{1.15 * 10$^4$} & \cellcolor{gray!6}{0.00490} & \cellcolor{gray!6}{0.00360} & \cellcolor{gray!6}{0.00619}\\
5.085 & 1.22 * 10$^5$ & 0.00407 & 0.00283 & 0.00531\\
\cellcolor{gray!6}{5.507} & \cellcolor{gray!6}{3.21 * 10$^5$} & \cellcolor{gray!6}{0.00377} & \cellcolor{gray!6}{0.00247} & \cellcolor{gray!6}{0.00507}\\
5.839 & 6.90 * 10$^5$ & 0.00288 & 0.00163 & 0.00414\\
\cellcolor{gray!6}{6.048} & \cellcolor{gray!6}{1.12 * 10$^6$} & \cellcolor{gray!6}{0.00238} & \cellcolor{gray!6}{0.00113} & \cellcolor{gray!6}{0.00364}\\
6.257 & 1.81 * 10$^6$ & 0.00159 & 0.00043 & 0.00275\\
\cellcolor{gray!6}{6.499} & \cellcolor{gray!6}{3.16 * 10$^6$} & \cellcolor{gray!6}{0.00124} & \cellcolor{gray!6}{0.00001} & \cellcolor{gray!6}{0.00248}\\
6.847 & 7.03 * 10$^6$ & 0.00064 & 0.00000 & 0.00155\\
\cellcolor{gray!6}{7.181} & \cellcolor{gray!6}{1.52 * 10$^7$} & \cellcolor{gray!6}{0.00064} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00255}\\
8.239 & 1.73 * 10$^8$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-pseudo-virus-neutralizing-antibody-50-titer-1}{%
\subsection{Day 57 Pseudo virus-neutralizing antibody (50\% titer)}\label{day-57-pseudo-virus-neutralizing-antibody-50-titer-1}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_monotone_Day57pseudoneutid50_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Pseudo virus-neutralizing antibody (50\% titer) levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-367}Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50\% titer) levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00508} & \cellcolor{gray!6}{0.00376} & \cellcolor{gray!6}{0.00639}\\
2.033 & 1.08 * 10$^2$ & 0.00390 & 0.00268 & 0.00512\\
\cellcolor{gray!6}{2.447} & \cellcolor{gray!6}{2.80 * 10$^2$} & \cellcolor{gray!6}{0.00347} & \cellcolor{gray!6}{0.00223} & \cellcolor{gray!6}{0.00471}\\
2.913 & 8.18 * 10$^2$ & 0.00272 & 0.00152 & 0.00392\\
\cellcolor{gray!6}{3.196} & \cellcolor{gray!6}{1.57 * 10$^3$} & \cellcolor{gray!6}{0.00235} & \cellcolor{gray!6}{0.00112} & \cellcolor{gray!6}{0.00358}\\
3.464 & 2.91 * 10$^3$ & 0.00126 & 0.00027 & 0.00225\\
\cellcolor{gray!6}{3.736} & \cellcolor{gray!6}{5.45 * 10$^3$} & \cellcolor{gray!6}{0.00126} & \cellcolor{gray!6}{0.00005} & \cellcolor{gray!6}{0.00247}\\
4.123 & 1.33 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\cellcolor{gray!6}{4.629} & \cellcolor{gray!6}{4.26 * 10$^4$} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{NA}\\
5.730 & 5.37 * 10$^5$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-pseudo-virus-neutralizing-antibody-80-titer-1}{%
\subsection{Day 57 Pseudo virus-neutralizing antibody (80\% titer)}\label{day-57-pseudo-virus-neutralizing-antibody-80-titer-1}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_monotone_Day57pseudoneutid80_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Pseudo virus-neutralizing antibody (80\% titer) levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-369}Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80\% titer) levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{1.289} & \cellcolor{gray!6}{1.95 * 10$^1$} & \cellcolor{gray!6}{0.00514} & \cellcolor{gray!6}{0.00381} & \cellcolor{gray!6}{0.00647}\\
2.368 & 2.33 * 10$^2$ & 0.00469 & 0.00334 & 0.00605\\
\cellcolor{gray!6}{2.755} & \cellcolor{gray!6}{5.69 * 10$^2$} & \cellcolor{gray!6}{0.00428} & \cellcolor{gray!6}{0.00290} & \cellcolor{gray!6}{0.00565}\\
3.104 & 1.27 * 10$^3$ & 0.00343 & 0.00203 & 0.00482\\
\cellcolor{gray!6}{3.373} & \cellcolor{gray!6}{2.36 * 10$^3$} & \cellcolor{gray!6}{0.00312} & \cellcolor{gray!6}{0.00171} & \cellcolor{gray!6}{0.00454}\\
3.624 & 4.21 * 10$^3$ & 0.00284 & 0.00130 & 0.00438\\
\cellcolor{gray!6}{3.909} & \cellcolor{gray!6}{8.11 * 10$^3$} & \cellcolor{gray!6}{0.00243} & \cellcolor{gray!6}{0.00083} & \cellcolor{gray!6}{0.00402}\\
4.259 & 1.82 * 10$^4$ & 0.00208 & 0.00015 & 0.00402\\
\cellcolor{gray!6}{4.676} & \cellcolor{gray!6}{4.74 * 10$^4$} & \cellcolor{gray!6}{0.00208} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00520}\\
5.796 & 6.25 * 10$^5$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\hypertarget{plots-and-tables-with-estimates-and-pointwise-confidence-intervals-for-day-29-monotone-corrected}{%
\section{Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)}\label{plots-and-tables-with-estimates-and-pointwise-confidence-intervals-for-day-29-monotone-corrected}}

\newpage

\newpage

\hypertarget{day-29-spike-protein-antibody-1}{%
\subsection{Day 29 Spike protein antibody}\label{day-29-spike-protein-antibody-1}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_monotone_Day29bindSpike_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Spike protein antibody levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-371}Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{3.202} & \cellcolor{gray!6}{1.59 * 10$^3$} & \cellcolor{gray!6}{0.00567} & \cellcolor{gray!6}{0.00427} & \cellcolor{gray!6}{0.00707}\\
3.926 & 8.43 * 10$^3$ & 0.00476 & 0.00341 & 0.00611\\
\cellcolor{gray!6}{4.187} & \cellcolor{gray!6}{1.54 * 10$^4$} & \cellcolor{gray!6}{0.00459} & \cellcolor{gray!6}{0.00317} & \cellcolor{gray!6}{0.00601}\\
4.478 & 3.01 * 10$^4$ & 0.00355 & 0.00215 & 0.00494\\
\cellcolor{gray!6}{4.658} & \cellcolor{gray!6}{4.55 * 10$^4$} & \cellcolor{gray!6}{0.00278} & \cellcolor{gray!6}{0.00138} & \cellcolor{gray!6}{0.00419}\\
4.841 & 6.93 * 10$^4$ & 0.00230 & 0.00083 & 0.00377\\
\cellcolor{gray!6}{5.022} & \cellcolor{gray!6}{1.05 * 10$^5$} & \cellcolor{gray!6}{0.00182} & \cellcolor{gray!6}{0.00031} & \cellcolor{gray!6}{0.00332}\\
5.310 & 2.04 * 10$^5$ & 0.00172 & 0.00000 & 0.00379\\
\cellcolor{gray!6}{5.523} & \cellcolor{gray!6}{3.33 * 10$^5$} & \cellcolor{gray!6}{0.00172} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00434}\\
6.259 & 1.82 * 10$^6$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-rbd-binding-antibody-1}{%
\subsection{Day 29 RBD binding antibody}\label{day-29-rbd-binding-antibody-1}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_monotone_Day29bindRBD_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 RBD binding antibody levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-373}Table of monotone-corrected risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{2.882} & \cellcolor{gray!6}{7.62 * 10$^2$} & \cellcolor{gray!6}{0.00576} & \cellcolor{gray!6}{0.00435} & \cellcolor{gray!6}{0.00718}\\
3.628 & 4.25 * 10$^3$ & 0.00523 & 0.00379 & 0.00666\\
\cellcolor{gray!6}{3.889} & \cellcolor{gray!6}{7.74 * 10$^3$} & \cellcolor{gray!6}{0.00459} & \cellcolor{gray!6}{0.00316} & \cellcolor{gray!6}{0.00602}\\
4.180 & 1.51 * 10$^4$ & 0.00452 & 0.00297 & 0.00607\\
\cellcolor{gray!6}{4.395} & \cellcolor{gray!6}{2.48 * 10$^4$} & \cellcolor{gray!6}{0.00452} & \cellcolor{gray!6}{0.00264} & \cellcolor{gray!6}{0.00640}\\
4.603 & 4.01 * 10$^4$ & 0.00414 & 0.00217 & 0.00611\\
\cellcolor{gray!6}{4.826} & \cellcolor{gray!6}{6.70 * 10$^4$} & \cellcolor{gray!6}{0.00365} & \cellcolor{gray!6}{0.00148} & \cellcolor{gray!6}{0.00583}\\
5.105 & 1.27 * 10$^5$ & 0.00112 & 0.00000 & 0.00261\\
\cellcolor{gray!6}{5.422} & \cellcolor{gray!6}{2.64 * 10$^5$} & \cellcolor{gray!6}{0.00112} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00314}\\
6.197 & 1.57 * 10$^6$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-pseudo-virus-neutralizing-antibody-50-titer-1}{%
\subsection{Day 29 Pseudo virus-neutralizing antibody (50\% titer)}\label{day-29-pseudo-virus-neutralizing-antibody-50-titer-1}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_monotone_Day29pseudoneutid50_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Pseudo virus-neutralizing antibody (50\% titer) levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-375}Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50\% titer) levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00585} & \cellcolor{gray!6}{0.00442} & \cellcolor{gray!6}{0.00727}\\
1.363 & 2.31 * 10$^1$ & 0.00470 & 0.00331 & 0.00610\\
\cellcolor{gray!6}{1.628} & \cellcolor{gray!6}{4.25 * 10$^1$} & \cellcolor{gray!6}{0.00468} & \cellcolor{gray!6}{0.00318} & \cellcolor{gray!6}{0.00619}\\
1.848 & 7.05 * 10$^1$ & 0.00445 & 0.00284 & 0.00606\\
\cellcolor{gray!6}{2.078} & \cellcolor{gray!6}{1.20 * 10$^2$} & \cellcolor{gray!6}{0.00411} & \cellcolor{gray!6}{0.00249} & \cellcolor{gray!6}{0.00573}\\
2.293 & 1.96 * 10$^2$ & 0.00343 & 0.00175 & 0.00511\\
\cellcolor{gray!6}{2.537} & \cellcolor{gray!6}{3.44 * 10$^2$} & \cellcolor{gray!6}{0.00164} & \cellcolor{gray!6}{0.00037} & \cellcolor{gray!6}{0.00291}\\
2.791 & 6.18 * 10$^2$ & 0.00164 & 0.00039 & 0.00290\\
\cellcolor{gray!6}{3.109} & \cellcolor{gray!6}{1.29 * 10$^3$} & \cellcolor{gray!6}{0.00164} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00446}\\
4.080 & 1.20 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-pseudo-virus-neutralizing-antibody-80-titer-1}{%
\subsection{Day 29 Pseudo virus-neutralizing antibody (80\% titer)}\label{day-29-pseudo-virus-neutralizing-antibody-80-titer-1}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/pointwise_CI/PLOT_monotone_Day29pseudoneutid80_pointwiseCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Pseudo virus-neutralizing antibody (80\% titer) levels with pointwise 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-377}Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80\% titer) levels with pointwise 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00585} & \cellcolor{gray!6}{0.00442} & \cellcolor{gray!6}{0.00727}\\
1.525 & 3.35 * 10$^1$ & 0.00554 & 0.00406 & 0.00701\\
\cellcolor{gray!6}{1.840} & \cellcolor{gray!6}{6.92 * 10$^1$} & \cellcolor{gray!6}{0.00554} & \cellcolor{gray!6}{0.00386} & \cellcolor{gray!6}{0.00721}\\
2.049 & 1.12 * 10$^2$ & 0.00545 & 0.00369 & 0.00721\\
\cellcolor{gray!6}{2.276} & \cellcolor{gray!6}{1.89 * 10$^2$} & \cellcolor{gray!6}{0.00534} & \cellcolor{gray!6}{0.00343} & \cellcolor{gray!6}{0.00726}\\
2.583 & 3.83 * 10$^2$ & 0.00515 & 0.00304 & 0.00726\\
\cellcolor{gray!6}{2.785} & \cellcolor{gray!6}{6.10 * 10$^2$} & \cellcolor{gray!6}{0.00515} & \cellcolor{gray!6}{0.00244} & \cellcolor{gray!6}{0.00786}\\
3.039 & 1.09 * 10$^3$ & 0.00349 & 0.00102 & 0.00596\\
\cellcolor{gray!6}{3.351} & \cellcolor{gray!6}{2.24 * 10$^3$} & \cellcolor{gray!6}{0.00242} & \cellcolor{gray!6}{0.00005} & \cellcolor{gray!6}{0.00480}\\
4.285 & 1.93 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\hypertarget{plots-and-tables-with-estimates-and-simultaneous-confidence-bands-for-day-57}{%
\section{Plots and Tables with estimates and simultaneous confidence bands for Day 57}\label{plots-and-tables-with-estimates-and-simultaneous-confidence-bands-for-day-57}}

\newpage

\newpage

\hypertarget{day-57-spike-protein-binding-antibody-2}{%
\subsection{Day 57 Spike protein binding antibody}\label{day-57-spike-protein-binding-antibody-2}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_Day57bindSpike_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Spike protein binding antibody levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-379}Table of risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{4.536} & \cellcolor{gray!6}{3.44 * 10$^4$} & \cellcolor{gray!6}{0.00480} & \cellcolor{gray!6}{0.00289} & \cellcolor{gray!6}{0.00671}\\
5.413 & 2.59 * 10$^5$ & 0.00271 & 0.00125 & 0.00418\\
\cellcolor{gray!6}{5.797} & \cellcolor{gray!6}{6.27 * 10$^5$} & \cellcolor{gray!6}{0.00172} & \cellcolor{gray!6}{0.00049} & \cellcolor{gray!6}{0.00296}\\
6.165 & 1.46 * 10$^6$ & 0.00115 & 0.00002 & 0.00228\\
\cellcolor{gray!6}{6.405} & \cellcolor{gray!6}{2.54 * 10$^6$} & \cellcolor{gray!6}{0.00079} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00185}\\
6.622 & 4.19 * 10$^6$ & 0.00021 & 0.00000 & 0.00085\\
\cellcolor{gray!6}{6.820} & \cellcolor{gray!6}{6.61 * 10$^6$} & \cellcolor{gray!6}{0.00028} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00116}\\
7.127 & 1.34 * 10$^7$ & 0.00000 & 0.00000 & NA\\
\cellcolor{gray!6}{7.409} & \cellcolor{gray!6}{2.56 * 10$^7$} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{NA}\\
8.244 & 1.75 * 10$^8$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-rbd-binding-antibody-2}{%
\subsection{Day 57 RBD binding antibody}\label{day-57-rbd-binding-antibody-2}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_Day57bindRBD_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 RBD binding antibody levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-381}Table of risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{4.062} & \cellcolor{gray!6}{1.15 * 10$^4$} & \cellcolor{gray!6}{0.00490} & \cellcolor{gray!6}{0.00302} & \cellcolor{gray!6}{0.00677}\\
5.085 & 1.22 * 10$^5$ & 0.00405 & 0.00226 & 0.00585\\
\cellcolor{gray!6}{5.507} & \cellcolor{gray!6}{3.21 * 10$^5$} & \cellcolor{gray!6}{0.00377} & \cellcolor{gray!6}{0.00188} & \cellcolor{gray!6}{0.00565}\\
5.839 & 6.90 * 10$^5$ & 0.00288 & 0.00106 & 0.00470\\
\cellcolor{gray!6}{6.048} & \cellcolor{gray!6}{1.12 * 10$^6$} & \cellcolor{gray!6}{0.00238} & \cellcolor{gray!6}{0.00056} & \cellcolor{gray!6}{0.00420}\\
6.257 & 1.81 * 10$^6$ & 0.00159 & 0.00000 & 0.00327\\
\cellcolor{gray!6}{6.499} & \cellcolor{gray!6}{3.16 * 10$^6$} & \cellcolor{gray!6}{0.00131} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00310}\\
6.847 & 7.03 * 10$^6$ & 0.00043 & 0.00000 & 0.00176\\
\cellcolor{gray!6}{7.181} & \cellcolor{gray!6}{1.52 * 10$^7$} & \cellcolor{gray!6}{0.00087} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00365}\\
8.239 & 1.73 * 10$^8$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-pseudo-virus-neutralizing-antibody-50-titer-2}{%
\subsection{Day 57 Pseudo virus-neutralizing antibody (50\% titer)}\label{day-57-pseudo-virus-neutralizing-antibody-50-titer-2}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_Day57pseudoneutid50_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Pseudo virus-neutralizing antibody (50\% titer) levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-383}Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50\% titer) levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00508} & \cellcolor{gray!6}{0.00314} & \cellcolor{gray!6}{0.00701}\\
2.033 & 1.08 * 10$^2$ & 0.00390 & 0.00211 & 0.00570\\
\cellcolor{gray!6}{2.447} & \cellcolor{gray!6}{2.80 * 10$^2$} & \cellcolor{gray!6}{0.00347} & \cellcolor{gray!6}{0.00165} & \cellcolor{gray!6}{0.00529}\\
2.913 & 8.18 * 10$^2$ & 0.00265 & 0.00089 & 0.00442\\
\cellcolor{gray!6}{3.196} & \cellcolor{gray!6}{1.57 * 10$^3$} & \cellcolor{gray!6}{0.00235} & \cellcolor{gray!6}{0.00055} & \cellcolor{gray!6}{0.00416}\\
3.464 & 2.91 * 10$^3$ & 0.00115 & 0.00000 & 0.00261\\
\cellcolor{gray!6}{3.736} & \cellcolor{gray!6}{5.45 * 10$^3$} & \cellcolor{gray!6}{0.00134} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00312}\\
4.123 & 1.33 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\cellcolor{gray!6}{4.629} & \cellcolor{gray!6}{4.26 * 10$^4$} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{NA}\\
5.730 & 5.37 * 10$^5$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-pseudo-virus-neutralizing-antibody-80-titer-2}{%
\subsection{Day 57 Pseudo virus-neutralizing antibody (80\% titer)}\label{day-57-pseudo-virus-neutralizing-antibody-80-titer-2}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_Day57pseudoneutid80_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Pseudo virus-neutralizing antibody (80\% titer) levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-385}Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80\% titer) levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{1.289} & \cellcolor{gray!6}{1.95 * 10$^1$} & \cellcolor{gray!6}{0.00514} & \cellcolor{gray!6}{0.00323} & \cellcolor{gray!6}{0.00706}\\
2.368 & 2.33 * 10$^2$ & 0.00469 & 0.00274 & 0.00665\\
\cellcolor{gray!6}{2.755} & \cellcolor{gray!6}{5.69 * 10$^2$} & \cellcolor{gray!6}{0.00428} & \cellcolor{gray!6}{0.00229} & \cellcolor{gray!6}{0.00626}\\
3.104 & 1.27 * 10$^3$ & 0.00343 & 0.00141 & 0.00544\\
\cellcolor{gray!6}{3.373} & \cellcolor{gray!6}{2.36 * 10$^3$} & \cellcolor{gray!6}{0.00310} & \cellcolor{gray!6}{0.00107} & \cellcolor{gray!6}{0.00514}\\
3.624 & 4.21 * 10$^3$ & 0.00284 & 0.00061 & 0.00506\\
\cellcolor{gray!6}{3.909} & \cellcolor{gray!6}{8.11 * 10$^3$} & \cellcolor{gray!6}{0.00244} & \cellcolor{gray!6}{0.00015} & \cellcolor{gray!6}{0.00474}\\
4.259 & 1.82 * 10$^4$ & 0.00206 & 0.00000 & 0.00485\\
\cellcolor{gray!6}{4.676} & \cellcolor{gray!6}{4.74 * 10$^4$} & \cellcolor{gray!6}{0.00256} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00705}\\
5.796 & 6.25 * 10$^5$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\hypertarget{plots-and-tables-with-estimates-and-simultaneous-confidence-bands-for-day-29}{%
\section{Plots and Tables with estimates and simultaneous confidence bands for Day 29}\label{plots-and-tables-with-estimates-and-simultaneous-confidence-bands-for-day-29}}

\newpage

\newpage

\hypertarget{day-29-spike-protein-antibody-2}{%
\subsection{Day 29 Spike protein antibody}\label{day-29-spike-protein-antibody-2}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_Day29bindSpike_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Spike protein antibody levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-387}Table of risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{3.202} & \cellcolor{gray!6}{1.59 * 10$^3$} & \cellcolor{gray!6}{0.00567} & \cellcolor{gray!6}{0.00364} & \cellcolor{gray!6}{0.00770}\\
3.926 & 8.43 * 10$^3$ & 0.00476 & 0.00280 & 0.00672\\
\cellcolor{gray!6}{4.187} & \cellcolor{gray!6}{1.54 * 10$^4$} & \cellcolor{gray!6}{0.00460} & \cellcolor{gray!6}{0.00254} & \cellcolor{gray!6}{0.00666}\\
4.478 & 3.01 * 10$^4$ & 0.00355 & 0.00153 & 0.00557\\
\cellcolor{gray!6}{4.658} & \cellcolor{gray!6}{4.55 * 10$^4$} & \cellcolor{gray!6}{0.00278} & \cellcolor{gray!6}{0.00076} & \cellcolor{gray!6}{0.00481}\\
4.841 & 6.93 * 10$^4$ & 0.00230 & 0.00017 & 0.00443\\
\cellcolor{gray!6}{5.022} & \cellcolor{gray!6}{1.05 * 10$^5$} & \cellcolor{gray!6}{0.00182} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00400}\\
5.310 & 2.04 * 10$^5$ & 0.00147 & 0.00000 & 0.00446\\
\cellcolor{gray!6}{5.523} & \cellcolor{gray!6}{3.33 * 10$^5$} & \cellcolor{gray!6}{0.00132} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00511}\\
6.259 & 1.82 * 10$^6$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-rbd-binding-antibody-2}{%
\subsection{Day 29 RBD binding antibody}\label{day-29-rbd-binding-antibody-2}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_Day29bindRBD_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 RBD binding antibody levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-389}Table of risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{2.882} & \cellcolor{gray!6}{7.62 * 10$^2$} & \cellcolor{gray!6}{0.00576} & \cellcolor{gray!6}{0.00374} & \cellcolor{gray!6}{0.00779}\\
3.628 & 4.25 * 10$^3$ & 0.00523 & 0.00318 & 0.00728\\
\cellcolor{gray!6}{3.889} & \cellcolor{gray!6}{7.74 * 10$^3$} & \cellcolor{gray!6}{0.00459} & \cellcolor{gray!6}{0.00255} & \cellcolor{gray!6}{0.00663}\\
4.180 & 1.51 * 10$^4$ & 0.00434 & 0.00211 & 0.00656\\
\cellcolor{gray!6}{4.395} & \cellcolor{gray!6}{2.48 * 10$^4$} & \cellcolor{gray!6}{0.00486} & \cellcolor{gray!6}{0.00217} & \cellcolor{gray!6}{0.00755}\\
4.603 & 4.01 * 10$^4$ & 0.00414 & 0.00132 & 0.00696\\
\cellcolor{gray!6}{4.826} & \cellcolor{gray!6}{6.70 * 10$^4$} & \cellcolor{gray!6}{0.00365} & \cellcolor{gray!6}{0.00054} & \cellcolor{gray!6}{0.00676}\\
5.105 & 1.27 * 10$^5$ & 0.00104 & 0.00000 & 0.00317\\
\cellcolor{gray!6}{5.422} & \cellcolor{gray!6}{2.64 * 10$^5$} & \cellcolor{gray!6}{0.00097} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00385}\\
6.197 & 1.57 * 10$^6$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-pseudo-virus-neutralizing-antibody-50-titer-2}{%
\subsection{Day 29 Pseudo virus-neutralizing antibody (50\% titer)}\label{day-29-pseudo-virus-neutralizing-antibody-50-titer-2}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_Day29pseudoneutid50_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Pseudo virus-neutralizing antibody (50\% titer) levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-391}Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50\% titer) levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00585} & \cellcolor{gray!6}{0.00382} & \cellcolor{gray!6}{0.00788}\\
1.363 & 2.31 * 10$^1$ & 0.00470 & 0.00271 & 0.00668\\
\cellcolor{gray!6}{1.628} & \cellcolor{gray!6}{4.25 * 10$^1$} & \cellcolor{gray!6}{0.00469} & \cellcolor{gray!6}{0.00254} & \cellcolor{gray!6}{0.00683}\\
1.848 & 7.05 * 10$^1$ & 0.00451 & 0.00222 & 0.00680\\
\cellcolor{gray!6}{2.078} & \cellcolor{gray!6}{1.20 * 10$^2$} & \cellcolor{gray!6}{0.00399} & \cellcolor{gray!6}{0.00168} & \cellcolor{gray!6}{0.00630}\\
2.293 & 1.96 * 10$^2$ & 0.00343 & 0.00104 & 0.00582\\
\cellcolor{gray!6}{2.537} & \cellcolor{gray!6}{3.44 * 10$^2$} & \cellcolor{gray!6}{0.00143} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00323}\\
2.791 & 6.18 * 10$^2$ & 0.00091 & 0.00000 & 0.00270\\
\cellcolor{gray!6}{3.109} & \cellcolor{gray!6}{1.29 * 10$^3$} & \cellcolor{gray!6}{0.00199} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00601}\\
4.080 & 1.20 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-pseudo-virus-neutralizing-antibody-80-titer-2}{%
\subsection{Day 29 Pseudo virus-neutralizing antibody (80\% titer)}\label{day-29-pseudo-virus-neutralizing-antibody-80-titer-2}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_Day29pseudoneutid80_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Pseudo virus-neutralizing antibody (80\% titer) levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. }
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-393}Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80\% titer) levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00585} & \cellcolor{gray!6}{0.00382} & \cellcolor{gray!6}{0.00788}\\
1.525 & 3.35 * 10$^1$ & 0.00535 & 0.00324 & 0.00745\\
\cellcolor{gray!6}{1.840} & \cellcolor{gray!6}{6.92 * 10$^1$} & \cellcolor{gray!6}{0.00580} & \cellcolor{gray!6}{0.00341} & \cellcolor{gray!6}{0.00819}\\
2.049 & 1.12 * 10$^2$ & 0.00554 & 0.00304 & 0.00805\\
\cellcolor{gray!6}{2.276} & \cellcolor{gray!6}{1.89 * 10$^2$} & \cellcolor{gray!6}{0.00542} & \cellcolor{gray!6}{0.00269} & \cellcolor{gray!6}{0.00814}\\
2.583 & 3.83 * 10$^2$ & 0.00479 & 0.00179 & 0.00780\\
\cellcolor{gray!6}{2.785} & \cellcolor{gray!6}{6.10 * 10$^2$} & \cellcolor{gray!6}{0.00559} & \cellcolor{gray!6}{0.00172} & \cellcolor{gray!6}{0.00945}\\
3.039 & 1.09 * 10$^3$ & 0.00342 & 0.00000 & 0.00694\\
\cellcolor{gray!6}{3.351} & \cellcolor{gray!6}{2.24 * 10$^3$} & \cellcolor{gray!6}{0.00161} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00499}\\
4.285 & 1.93 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\hypertarget{plots-and-tables-with-estimates-and-pointwise-confidence-interval-for-day-57-monotone-corrected-1}{%
\section{Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)}\label{plots-and-tables-with-estimates-and-pointwise-confidence-interval-for-day-57-monotone-corrected-1}}

\newpage

\newpage

\hypertarget{day-57-spike-protein-binding-antibody-3}{%
\subsection{Day 57 Spike protein binding antibody}\label{day-57-spike-protein-binding-antibody-3}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_monotone_Day57bindSpike_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Spike protein binding antibody levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-395}Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{4.536} & \cellcolor{gray!6}{3.44 * 10$^4$} & \cellcolor{gray!6}{0.00480} & \cellcolor{gray!6}{0.00289} & \cellcolor{gray!6}{0.00671}\\
5.413 & 2.59 * 10$^5$ & 0.00271 & 0.00125 & 0.00418\\
\cellcolor{gray!6}{5.797} & \cellcolor{gray!6}{6.27 * 10$^5$} & \cellcolor{gray!6}{0.00172} & \cellcolor{gray!6}{0.00049} & \cellcolor{gray!6}{0.00296}\\
6.165 & 1.46 * 10$^6$ & 0.00115 & 0.00002 & 0.00228\\
\cellcolor{gray!6}{6.405} & \cellcolor{gray!6}{2.54 * 10$^6$} & \cellcolor{gray!6}{0.00083} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00189}\\
6.622 & 4.19 * 10$^6$ & 0.00024 & 0.00000 & 0.00089\\
\cellcolor{gray!6}{6.820} & \cellcolor{gray!6}{6.61 * 10$^6$} & \cellcolor{gray!6}{0.00024} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00112}\\
7.127 & 1.34 * 10$^7$ & 0.00000 & 0.00000 & NA\\
\cellcolor{gray!6}{7.409} & \cellcolor{gray!6}{2.56 * 10$^7$} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{NA}\\
8.244 & 1.75 * 10$^8$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-rbd-binding-antibody-3}{%
\subsection{Day 57 RBD binding antibody}\label{day-57-rbd-binding-antibody-3}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_monotone_Day57bindRBD_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 RBD binding antibody levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-397}Table of monotone-corrected risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{4.062} & \cellcolor{gray!6}{1.15 * 10$^4$} & \cellcolor{gray!6}{0.00490} & \cellcolor{gray!6}{0.00302} & \cellcolor{gray!6}{0.00677}\\
5.085 & 1.22 * 10$^5$ & 0.00407 & 0.00228 & 0.00586\\
\cellcolor{gray!6}{5.507} & \cellcolor{gray!6}{3.21 * 10$^5$} & \cellcolor{gray!6}{0.00377} & \cellcolor{gray!6}{0.00188} & \cellcolor{gray!6}{0.00565}\\
5.839 & 6.90 * 10$^5$ & 0.00288 & 0.00106 & 0.00470\\
\cellcolor{gray!6}{6.048} & \cellcolor{gray!6}{1.12 * 10$^6$} & \cellcolor{gray!6}{0.00238} & \cellcolor{gray!6}{0.00056} & \cellcolor{gray!6}{0.00420}\\
6.257 & 1.81 * 10$^6$ & 0.00159 & 0.00000 & 0.00327\\
\cellcolor{gray!6}{6.499} & \cellcolor{gray!6}{3.16 * 10$^6$} & \cellcolor{gray!6}{0.00124} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00304}\\
6.847 & 7.03 * 10$^6$ & 0.00064 & 0.00000 & 0.00196\\
\cellcolor{gray!6}{7.181} & \cellcolor{gray!6}{1.52 * 10$^7$} & \cellcolor{gray!6}{0.00064} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00341}\\
8.239 & 1.73 * 10$^8$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-pseudo-virus-neutralizing-antibody-50-titer-3}{%
\subsection{Day 57 Pseudo virus-neutralizing antibody (50\% titer)}\label{day-57-pseudo-virus-neutralizing-antibody-50-titer-3}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_monotone_Day57pseudoneutid50_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Pseudo virus-neutralizing antibody (50\% titer) levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-399}Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50\% titer) levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00508} & \cellcolor{gray!6}{0.00314} & \cellcolor{gray!6}{0.00701}\\
2.033 & 1.08 * 10$^2$ & 0.00390 & 0.00211 & 0.00570\\
\cellcolor{gray!6}{2.447} & \cellcolor{gray!6}{2.80 * 10$^2$} & \cellcolor{gray!6}{0.00347} & \cellcolor{gray!6}{0.00165} & \cellcolor{gray!6}{0.00529}\\
2.913 & 8.18 * 10$^2$ & 0.00272 & 0.00095 & 0.00448\\
\cellcolor{gray!6}{3.196} & \cellcolor{gray!6}{1.57 * 10$^3$} & \cellcolor{gray!6}{0.00235} & \cellcolor{gray!6}{0.00055} & \cellcolor{gray!6}{0.00416}\\
3.464 & 2.91 * 10$^3$ & 0.00126 & 0.00000 & 0.00272\\
\cellcolor{gray!6}{3.736} & \cellcolor{gray!6}{5.45 * 10$^3$} & \cellcolor{gray!6}{0.00126} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00304}\\
4.123 & 1.33 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\cellcolor{gray!6}{4.629} & \cellcolor{gray!6}{4.26 * 10$^4$} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{NA}\\
5.730 & 5.37 * 10$^5$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-57-pseudo-virus-neutralizing-antibody-80-titer-3}{%
\subsection{Day 57 Pseudo virus-neutralizing antibody (80\% titer)}\label{day-57-pseudo-virus-neutralizing-antibody-80-titer-3}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_monotone_Day57pseudoneutid80_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 57 Pseudo virus-neutralizing antibody (80\% titer) levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-401}Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80\% titer) levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{1.289} & \cellcolor{gray!6}{1.95 * 10$^1$} & \cellcolor{gray!6}{0.00514} & \cellcolor{gray!6}{0.00323} & \cellcolor{gray!6}{0.00706}\\
2.368 & 2.33 * 10$^2$ & 0.00469 & 0.00274 & 0.00665\\
\cellcolor{gray!6}{2.755} & \cellcolor{gray!6}{5.69 * 10$^2$} & \cellcolor{gray!6}{0.00428} & \cellcolor{gray!6}{0.00229} & \cellcolor{gray!6}{0.00626}\\
3.104 & 1.27 * 10$^3$ & 0.00343 & 0.00141 & 0.00544\\
\cellcolor{gray!6}{3.373} & \cellcolor{gray!6}{2.36 * 10$^3$} & \cellcolor{gray!6}{0.00312} & \cellcolor{gray!6}{0.00108} & \cellcolor{gray!6}{0.00516}\\
3.624 & 4.21 * 10$^3$ & 0.00284 & 0.00061 & 0.00506\\
\cellcolor{gray!6}{3.909} & \cellcolor{gray!6}{8.11 * 10$^3$} & \cellcolor{gray!6}{0.00243} & \cellcolor{gray!6}{0.00013} & \cellcolor{gray!6}{0.00473}\\
4.259 & 1.82 * 10$^4$ & 0.00208 & 0.00000 & 0.00487\\
\cellcolor{gray!6}{4.676} & \cellcolor{gray!6}{4.74 * 10$^4$} & \cellcolor{gray!6}{0.00208} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00657}\\
5.796 & 6.25 * 10$^5$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\hypertarget{plots-and-tables-with-estimates-and-pointwise-confidence-intervals-for-day-29-monotone-corrected-1}{%
\section{Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)}\label{plots-and-tables-with-estimates-and-pointwise-confidence-intervals-for-day-29-monotone-corrected-1}}

\newpage

\newpage

\hypertarget{day-29-spike-protein-antibody-3}{%
\subsection{Day 29 Spike protein antibody}\label{day-29-spike-protein-antibody-3}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_monotone_Day29bindSpike_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Spike protein antibody levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-403}Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{3.202} & \cellcolor{gray!6}{1.59 * 10$^3$} & \cellcolor{gray!6}{0.00567} & \cellcolor{gray!6}{0.00364} & \cellcolor{gray!6}{0.00770}\\
3.926 & 8.43 * 10$^3$ & 0.00476 & 0.00280 & 0.00672\\
\cellcolor{gray!6}{4.187} & \cellcolor{gray!6}{1.54 * 10$^4$} & \cellcolor{gray!6}{0.00459} & \cellcolor{gray!6}{0.00253} & \cellcolor{gray!6}{0.00665}\\
4.478 & 3.01 * 10$^4$ & 0.00355 & 0.00153 & 0.00557\\
\cellcolor{gray!6}{4.658} & \cellcolor{gray!6}{4.55 * 10$^4$} & \cellcolor{gray!6}{0.00278} & \cellcolor{gray!6}{0.00076} & \cellcolor{gray!6}{0.00481}\\
4.841 & 6.93 * 10$^4$ & 0.00230 & 0.00017 & 0.00443\\
\cellcolor{gray!6}{5.022} & \cellcolor{gray!6}{1.05 * 10$^5$} & \cellcolor{gray!6}{0.00182} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00400}\\
5.310 & 2.04 * 10$^5$ & 0.00172 & 0.00000 & 0.00472\\
\cellcolor{gray!6}{5.523} & \cellcolor{gray!6}{3.33 * 10$^5$} & \cellcolor{gray!6}{0.00172} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00551}\\
6.259 & 1.82 * 10$^6$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-rbd-binding-antibody-3}{%
\subsection{Day 29 RBD binding antibody}\label{day-29-rbd-binding-antibody-3}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_monotone_Day29bindRBD_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 RBD binding antibody levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-405}Table of monotone-corrected risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{2.882} & \cellcolor{gray!6}{7.62 * 10$^2$} & \cellcolor{gray!6}{0.00576} & \cellcolor{gray!6}{0.00374} & \cellcolor{gray!6}{0.00779}\\
3.628 & 4.25 * 10$^3$ & 0.00523 & 0.00318 & 0.00728\\
\cellcolor{gray!6}{3.889} & \cellcolor{gray!6}{7.74 * 10$^3$} & \cellcolor{gray!6}{0.00459} & \cellcolor{gray!6}{0.00255} & \cellcolor{gray!6}{0.00663}\\
4.180 & 1.51 * 10$^4$ & 0.00452 & 0.00230 & 0.00674\\
\cellcolor{gray!6}{4.395} & \cellcolor{gray!6}{2.48 * 10$^4$} & \cellcolor{gray!6}{0.00452} & \cellcolor{gray!6}{0.00183} & \cellcolor{gray!6}{0.00721}\\
4.603 & 4.01 * 10$^4$ & 0.00414 & 0.00132 & 0.00696\\
\cellcolor{gray!6}{4.826} & \cellcolor{gray!6}{6.70 * 10$^4$} & \cellcolor{gray!6}{0.00365} & \cellcolor{gray!6}{0.00054} & \cellcolor{gray!6}{0.00676}\\
5.105 & 1.27 * 10$^5$ & 0.00112 & 0.00000 & 0.00325\\
\cellcolor{gray!6}{5.422} & \cellcolor{gray!6}{2.64 * 10$^5$} & \cellcolor{gray!6}{0.00112} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00400}\\
6.197 & 1.57 * 10$^6$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-pseudo-virus-neutralizing-antibody-50-titer-3}{%
\subsection{Day 29 Pseudo virus-neutralizing antibody (50\% titer)}\label{day-29-pseudo-virus-neutralizing-antibody-50-titer-3}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_monotone_Day29pseudoneutid50_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Pseudo virus-neutralizing antibody (50\% titer) levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-407}Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50\% titer) levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00585} & \cellcolor{gray!6}{0.00382} & \cellcolor{gray!6}{0.00788}\\
1.363 & 2.31 * 10$^1$ & 0.00470 & 0.00272 & 0.00669\\
\cellcolor{gray!6}{1.628} & \cellcolor{gray!6}{4.25 * 10$^1$} & \cellcolor{gray!6}{0.00468} & \cellcolor{gray!6}{0.00254} & \cellcolor{gray!6}{0.00683}\\
1.848 & 7.05 * 10$^1$ & 0.00445 & 0.00216 & 0.00674\\
\cellcolor{gray!6}{2.078} & \cellcolor{gray!6}{1.20 * 10$^2$} & \cellcolor{gray!6}{0.00411} & \cellcolor{gray!6}{0.00180} & \cellcolor{gray!6}{0.00642}\\
2.293 & 1.96 * 10$^2$ & 0.00343 & 0.00104 & 0.00582\\
\cellcolor{gray!6}{2.537} & \cellcolor{gray!6}{3.44 * 10$^2$} & \cellcolor{gray!6}{0.00164} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00345}\\
2.791 & 6.18 * 10$^2$ & 0.00164 & 0.00000 & 0.00343\\
\cellcolor{gray!6}{3.109} & \cellcolor{gray!6}{1.29 * 10$^3$} & \cellcolor{gray!6}{0.00164} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00565}\\
4.080 & 1.20 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\newpage

\newpage

\hypertarget{day-29-pseudo-virus-neutralizing-antibody-80-titer-3}{%
\subsection{Day 29 Pseudo virus-neutralizing antibody (80\% titer)}\label{day-29-pseudo-virus-neutralizing-antibody-80-titer-3}}

\begin{figure}[H]
\centering
\includegraphics[width=0.75\textwidth]{/home/travis/build/CoVPN/correlates_reporting/cor_threshold/figs/simultaneous_CI/PLOT_monotone_Day29pseudoneutid80_simultCI.pdf}
\caption{Adjusted threshold-response function for a range of thresholds of the
  Day 29 Pseudo virus-neutralizing antibody (80\% titer) levels with simultaneous 95\% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.}
\end{figure}
\begin{table}[!h]

\caption{\label{tab:unnamed-chunk-409}Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80\% titer) levels with simultaneous 95\% confidence intervals.}
\centering
\begin{tabular}[t]{rlrrr}
\toprule
log$_{10}$-Threshold & Threshold & Risk estimate & CI left & CI right\\
\midrule
\cellcolor{gray!6}{0.699} & \cellcolor{gray!6}{5.00 * 10$^0$} & \cellcolor{gray!6}{0.00585} & \cellcolor{gray!6}{0.00382} & \cellcolor{gray!6}{0.00788}\\
1.525 & 3.35 * 10$^1$ & 0.00554 & 0.00343 & 0.00764\\
\cellcolor{gray!6}{1.840} & \cellcolor{gray!6}{6.92 * 10$^1$} & \cellcolor{gray!6}{0.00554} & \cellcolor{gray!6}{0.00314} & \cellcolor{gray!6}{0.00793}\\
2.049 & 1.12 * 10$^2$ & 0.00545 & 0.00294 & 0.00796\\
\cellcolor{gray!6}{2.276} & \cellcolor{gray!6}{1.89 * 10$^2$} & \cellcolor{gray!6}{0.00534} & \cellcolor{gray!6}{0.00262} & \cellcolor{gray!6}{0.00807}\\
2.583 & 3.83 * 10$^2$ & 0.00515 & 0.00215 & 0.00816\\
\cellcolor{gray!6}{2.785} & \cellcolor{gray!6}{6.10 * 10$^2$} & \cellcolor{gray!6}{0.00515} & \cellcolor{gray!6}{0.00129} & \cellcolor{gray!6}{0.00902}\\
3.039 & 1.09 * 10$^3$ & 0.00349 & 0.00000 & 0.00701\\
\cellcolor{gray!6}{3.351} & \cellcolor{gray!6}{2.24 * 10$^3$} & \cellcolor{gray!6}{0.00242} & \cellcolor{gray!6}{0.00000} & \cellcolor{gray!6}{0.00581}\\
4.285 & 1.93 * 10$^4$ & 0.00000 & 0.00000 & NA\\
\bottomrule
\end{tabular}
\end{table}

\newpage

\bibliography{book.bib,packages.bib}

\end{document}
